<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2110246083
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CLAZ MR 60 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GLICLAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        modified-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BB09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- How CLAZ MR works</strong></p><p>The active ingredient in CLAZ MR is gliclazide. Gliclazide belongs to a group of medicines called the sulfonylureas.</p><p>Gliclazide lowers high blood glucose by increasing the amount of insulin produced by your pancreas.</p><p>Glucose is used by the body as fuel, and all people have glucose circulating in their blood.</p><p>The medicine is used to control blood glucose in patients with Type II diabetes mellitus.</p><p>This type of diabetes is also known as non-insulin-dependent diabetes mellitus (NIDDM) or maturity onset diabetes.</p><p>CLAZ MR is used when diet and exercise are not enough to control your blood glucose.</p><p>CLAZ MR can be used alone, or together with other medicines for treating diabetes.</p><p>Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason.</p><p>This medicine is available only with a doctor&#39;s prescription.</p><p>In diabetes, levels of blood glucose are higher than is needed. This is called hyperglycemia.</p><p>A section at the end of this leaflet contains advice about recognizing and treating hyperglycemia.</p><p>It is very important to control high blood glucose whether or not you feel unwell. This really helps to avoid serious long-term health problems, which can involve the heart, eyes, circulation, and/or kidneys.</p><p>As with many medicines used for the treatment of diabetes, there is a possibility that blood glucose levels may become very low during treatment with gliclazide. This is known as hypoglycemia.</p><p>A section at the end of this leaflet contains advice about recognizing and treating hypoglycemia.</p><p>There is no evidence that this medicine is addictive.</p><p>&nbsp;</p><p><strong>b- Use in children</strong></p><p>This medicine should not be used in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- Do not take CLAZ MR if:</strong></p><ul><li>The expiry date (EXP) printed on the pack has passed</li><li>The packaging is torn, shows signs of tampering or it does not look quite right</li><li>You have Type I diabetes mellitus (insulin dependent diabetes mellitus, also known as IDDM, or juvenile or growth onset diabetes)</li><li>You have unstable or brittle diabetes</li><li>You have diabetic acidosis</li><li>You have diabetic coma or pre-coma</li><li>You have a history of repeated ketoacidosis or coma</li><li>You have severe kidney disease</li><li>You have severe liver disease.</li><li>You are using miconazole to treat fungal infections</li><li>You are taking medicines called phenylbutazone or danazol</li><li>You have had an allergic reaction to:<ul><li>gliclazide or other sulfonylureas</li><li>antibiotics called sulfonamides</li><li>thiazide diuretics (a type of &quot;fluid&quot; or &quot;water&quot; tablet)</li><li>any of the ingredients listed at the end of this leaflet.</li></ul></li></ul><p>Symptoms of an allergic reaction may include cough, shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin; fainting or hayfever- like symptoms.</p><p>If you think you are having an allergic reaction, do not take any more of the medicine and contact your doctor immediately or go to the Accident and Emergency department at the nearest hospital.</p><p>Symptoms of an allergic reaction may include some or all of the following:</p><ul><li>cough, shortness of breath, wheezing or difficulty breathing</li><li>swelling of the face, lips, tongue, throat or other parts of the body</li><li>severe rash, itching or hives on the skin</li><li>fainting</li><li>hayfever-like symptoms.</li></ul><p>&nbsp;</p><p><strong>b- Pregnancy and breast-feeding</strong></p><p>CLAZ MR may affect your developing baby if you take it during pregnancy. Your doctor will usually replace CLAZ MR with insulin while you are pregnant.</p><p>It is not known whether CLAZ MR passes into human breast milk. Do not take this medicine whilst breast-feeding until you and your doctor have discussed the risks and benefits involved.</p><p>&nbsp;</p><p><strong>c- Take special care</strong></p><p>Remember to keep checking your blood glucose levels.</p><p>Before you start taking this medicine, tell your doctor if you:</p><ul><li>have allergies to any other medicines or any other substances, such as foods, preservatives or dyes.</li><li>have or have had any medical conditions, especially the following:<ul><li>kidney problems</li><li>liver problems</li><li>a growth in your pancreas, called an insulinoma</li><li>a history of diabetic coma</li><li>adrenal, pituitary or thyroid problems</li><li>heart failure</li><li>a condition called Glucose-6- Phosphate dehydrogenase Deficiency (G6PD)</li></ul></li><li>have any medical condition, or do anything, that may increase the risk of hyperglycemia &ndash; for example:<ul><li>you are ill or feeling unwell (especially with fever or infection)</li><li>you are injured</li><li>you are having surgery</li><li>you are taking less CLAZ MR than prescribed</li><li>you are doing less exercise than normal</li><li>you are eating more carbohydrates than normal</li></ul></li><li>You are taking a medicine called a beta-blocker. Taking this may mask the symptoms of diabetes.</li><li>You have any medical condition, or do anything, that may increase the risk of hypoglycemia &ndash; for example:<ul><li>drinking alcoholic drinks</li><li>not eating regular meals, including breakfast</li><li>doing more exercise than usual</li><li>eating less carbohydrate than normal</li></ul></li></ul><p>Alcohol, diet, exercise, and your general health all strongly affect the control of your diabetes.</p><ul><li>You do not have regular meals.</li><li>You are taking or are planning to take any other medicines. This includes vitamins and supplements that are available from your pharmacy, supermarket or health food shop.</li><li>If you are travelling, it is a good idea to:<ul><li>wear some form of identification showing you have diabetes</li><li>carry some form of sugar to treat hypoglycemia (low blood glucose) if it occurs, for example, sugar sachets or jelly beans</li><li>carry emergency food rations in case of a delay, for example, dried fruit, biscuits or muesli bars</li><li>keep CLAZ MR tablets readily available.</li></ul></li></ul><p>&nbsp;</p><p>If you become sick with a cold, fever or flu, it is very important to continue taking CLAZ MR, even if you feel unable to eat your normal meal.</p><p>If you have trouble eating solid food, use sugar-sweetened drinks as a carbohydrate substitute or eat small amounts of bland food.</p><p>Your diabetes educator or dietician can give you a list of foods to use for sick days.</p><p>&nbsp;</p><p><strong>d- Driving and using machines</strong></p><p>Be careful driving or operating machinery until you know how CLAZ MR affects you.</p><p>CLAZ MR may cause dizziness and drowsiness in some people.</p><p>Drinking alcohol can make this worse. If you do feel dizzy or drowsy, do not drive, operate machinery or do anything else that could be dangerous.</p><p>Be careful not to let your blood glucose levels fall too low.</p><p>Low blood glucose levels may slow your reaction time and affect your ability to drive or operate machinery.</p><p>A section at the end of this leaflet contains advice about recognizing and treating hypoglycemia.</p><p>&nbsp;</p><p><strong>e- Interactions with this medication:</strong></p><p>Some medicines may interact with CLAZ MR. These include:</p><ul><li>other medicines used to treat diabetes (tablets and insulin)</li><li>some medicines used to treat high blood pressure and other heart conditions, such as beta-blockers, ACE inhibitors</li><li>some hormones used in hormone replacement therapy and oral contraceptives (oestrogens and progestogens)</li><li>monoamine oxidase inhibitors (MAOIs), used for treating depression, Parkinsons Disease or infections</li><li>some medicines used for mental illness (e.g. chlorpromazine)</li><li>some medicines for epilepsy such as phenobarbitone</li><li>clofibrate, a medicine for lowering cholesterol</li><li>medicines used to treat arthritis, pain and inflammation (e.g. oxyphenbutazone, phenylbutazone, high dose salicylates)</li><li>antibiotics called sulfonamides, or chloramphenicol</li><li>miconazole, or fluconazole, used to treat fungal infections</li><li>some medicines used to prevent blood clots (warfarin and similar medicines)</li><li>cimetidine and similar medicines used to treat acid reflux and stomach ulcers</li><li>steroid medicines called glucocorticoids (e.g. prednisolone, cortisone)</li><li>some medicines for hormonal disturbances (such as danazol)</li><li>salbutamol and terbutaline, medicines for asthma</li><li>diuretics, also known as fluid tablets (e.g. chlorothiazide)</li></ul><p>If you are taking any of these you may need a different dose or you may need to take different medicines. Other medicines not listed above may also interact with CLAZ MR.</p><p>Drinking alcohol can also affect your blood sugar levels and how well CLAZ MR works. If taken with CLAZ MR, it can also cause flushing of the face, throbbing headache, giddiness, fast breathing, fast heart rate, angina, stomach pains or feeling sick or vomiting.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all directions given to you by your doctor or pharmacist or diabetes educator.</p><p>Their instructions may be different to the information in this leaflet.</p><p>The tablets release the CLAZ MR gradually over 24 hours.</p><p>&nbsp;</p><p><strong>a- How much CLAZ MR to take</strong></p><p>Your doctor or pharmacist will tell you how much of this medicine you should take. This will depend on your condition and whether you are taking any other medicines.</p><p>The starting dose is usually 30 mg per day (a half tablet of Claz MR 60mg or a tablet of Claz MR 30mg). This will be adjusted slowly over several weeks, depending on how well your body responds to the dose.</p><p>The usual dose of this medicine may vary from one to four tablets each day.</p><p>Your doctor may increase or decrease the dose, depending on your blood glucose levels.</p><p>Do not stop taking your medicine or change your dosage without first checking with your doctor.</p><p>&nbsp;</p><p><strong>b- How and When to take CLAZ MR</strong></p><p>Swallow the tablets whole with a glass of water. Do not crush the tablets or break them.</p><p>Take it at about the same time each day, usually with breakfast.</p><p>Taking these tablets with food can help to minimize the risk of hypoglycemia.</p><p>It will also help you remember when to take them.</p><p>Do not skip meals while taking these tablets.</p><p>CLAZ MR can help to control your blood glucose level, but it cannot cure your Type 2 diabetes.</p><p>CLAZ MR treatment is usually for a long period of time - so you should keep taking the tablets regularly unless advised otherwise by your doctor.</p><p>Make sure you have enough to last over weekends and holidays.</p><p>&nbsp;</p><p><strong>c- If you take more CLAZ MR than should</strong></p><p>If you think that you or anyone else may have taken too much of this medicine, immediately telephone your doctor or the Poisons Information Centre for advice. Alternatively, go to the Accident and Emergency Department at your nearest hospital.</p><p>Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.</p><p>If you take too much CLAZ MR you may experience symptoms of hypoglycemia (low blood glucose).</p><p>If not treated quickly, these symptoms may progress to loss of co-ordination, slurred speech, confusion, loss of consciousness and fitting.</p><p>At the first signs of hypoglycemia (low blood glucose), raise your blood glucose quickly by taking jelly beans, sugar or honey, (non- diet) soft drink or glucose tablets.</p><p>Note that artificial sweeteners will not help to raise your blood sugar levels.</p><p>&nbsp;</p><p><strong>d- If you forget to take CLAZ MR </strong></p><p>Take your next planned dose at the usual time and continue as normal.</p><p>Do not take a double dose to make up for the dose that you missed.</p><p>If you double a dose, this may cause hypoglycemia (low blood glucose).</p><p>If you are not sure what to do, ask your doctor or pharmacist. If you have trouble remembering to take your medicine, ask your pharmacist for some hints to help you remember.</p><p>&nbsp;</p><p><strong>e- While you are taking CLAZ MR</strong></p><p>Take your tablets exactly as your doctor has prescribed, otherwise you may not get the full benefits from treatment.</p><p>Make sure you check your blood glucose levels regularly. This is the best way to tell if your diabetes is being controlled properly. Your doctor or diabetes educator will show you how and when to do this.</p><p>Make sure that you, your friends, family and work colleagues can recognize the symptoms of hypoglycemia (low blood glucose) and hyperglycemia (high blood glucose) and know what to do.</p><p>Instructions at the end of this leaflet can help you with this.</p><p>Visit your doctor for regular blood tests and checks of your eyes, feet, kidneys, heart, circulation, blood, and blood pressure.</p><p>Carefully follow&nbsp;your doctor&#39;s and dietician&rsquo;s advice on diet, drinking alcohol and exercise.</p><p>Tell your doctor immediately if you notice the return of any symptoms of hyperglycemia that you had before starting CLAZ MR, or if your blood sugar levels are high.</p><p>These may be signs that CLAZ MR is no longer working, even though you may have been taking it successfully for some time.</p><p>If you are elderly or are taking other medicines for diabetes such as insulin or metformin, the risk of hypoglycemia (low blood glucose) is increased.</p><p>The risk of hypoglycemia (low blood glucose) is also increased in the following situations:</p><ul><li>too much CLAZ MR</li><li>too much or unexpected exercise</li><li>delayed meal or snack</li><li>too little food.</li></ul><p>&nbsp;</p><p>If you experience any of the signs of high blood glucose (hyperglycemia), contact your doctor immediately.</p><p>The risk of hyperglycemia (high blood glucose) is increased in the following situations:</p><ul><li>undiagnosed or uncontrolled diabetes</li><li>llness, infection or stress</li><li>too little CLAZ MR</li><li>certain other medicines</li><li>too little exercise</li><li>eating more carbohydrate than normal.</li></ul><p>&nbsp;</p><p>If you become ill or experience extra stress, injury, fever, infection or need surgery, tell your doctor.</p><p>Your blood glucose may become difficult to control at these times. Your doctor may decide to change your treatment and use insulin instead of CLAZ MR.</p><p>&nbsp;</p><p><strong>f- Recognizing and treating hypoglycemia (very low blood sugar levels)</strong></p><p>Hypoglycemia may occur during treatment with CLAZ MR. The first signs of hypoglycemia may include weakness, trembling or shaking, sweating, anxiety, changes in heart rate and breathing, light-headedness, dizziness, problems with sight, headache or lack of concentration, irritability, depression, aggression, tearfulness, hunger, nausea, vomiting, chest pain and/ or numbness around the lips and tongue. These symptoms can occur suddenly.</p><p>&nbsp;</p><p>If not treated promptly, these may progress to:</p><ul><li>loss of co-ordination</li><li>slurred speech</li><li>confusion, drowsiness</li><li>loss of consciousness or fitting.</li></ul><p>&nbsp;</p><p>At the first signs of hypoglycemia take some sugar to raise your blood sugar level quickly.</p><p>&nbsp;</p><p>Do this by taking one of the following:</p><ul><li>5-7 jelly beans</li><li>3 teaspoons of sugar or honey</li><li>half a can of ordinary (non-diet) soft drink</li><li>2-3 concentrated glucose tablets</li><li>a tube of glucose gel</li></ul><p>&nbsp;</p><p>Note that taking artificial sweeteners will not help raise your blood sugar levels.</p><p>Then take some extra carbohydrates such as plain biscuits, fruit or milk - unless you are within 10-15 minutes of your next meal. Taking this extra carbohydrate will help to prevent a second drop in your blood glucose level.</p><p>&nbsp;</p><p><strong>g- Recognizing and treating hyperglycemia (high blood sugar levels)</strong></p><p>If hypoglycemia symptoms do not get better straight away after taking sugar, or the symptoms are severe or prolonged, then go to the Accident and Emergency department at your nearest hospital - if necessary by calling an ambulance.</p><p>Contact your doctor or diabetes educator for advice if you are concerned about hypoglycemia.</p><p>Some people may feel fine when their glucose levels are high.</p><p>High blood glucose usually occurs more slowly than low blood glucose. Signs of high blood glucose may include:</p><ul><li>lethargy or tiredness</li><li>headache</li><li>thirst</li><li>passing large amounts of urine</li><li>blurred vision.</li></ul><p>If you notice symptoms of hyperglycemia, or your blood sugar levels are high, tell your doctor immediately. You may need adjustments of the dose or type of medicines you are taking.</p><p>It is very important to control high blood glucose whether or not you feel unwell. This really helps to avoid serious long-term health problems, which can involve the heart, eyes, circulation, and/or kidneys.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor, pharmacist, or diabetes educator as soon as possible if you do not feel well while you are taking CLAZ MR or if you have any questions or concerns.</p><p>Do not be alarmed by the following lists of side effects. You may not experience any of them. All medicines can have side effects. Sometimes they are serious but most of the time they are not.</p><p>Tell your doctor or pharmacist if you notice any of the following and they worry you.</p><p>This list includes the more common side effects. Mostly, these are mild:</p><ul><li>stomach upset including nausea and vomiting (feeling or being sick), heartburn, diarrhoea, constipation or a feeling of fullness in the stomach</li><li>sight problems (this may happen when you first start taking this medicine and your blood sugar levels change)</li><li>weariness</li><li>dizziness or giddiness</li><li>headache</li><li>mild rash or redness of the skin.</li></ul><p>Tell your doctor as soon as possible if you notice any of the following.</p><p>These may be serious side effects. You may need medical attention. Most of these side effects are rare.</p><ul><li>hypoglycemia or hyperglycemia. A section at the end of this leaflet contains advice about recognizing and treating hypoglycemia or hyperglycemia.</li><li>signs of frequent or worrying infections such as fever, severe chills, sore throat or mouth ulcers</li><li>signs of anemia such as tiredness, being short of breath and looking pale</li><li>bleeding or bruising more easily than normal, reddish or purplish blotches under the skin</li><li>itchy, red veins.</li></ul><p>If you experience any of the following, stop taking your medicine and contact your doctor immediately or go to the Accident and Emergency department at your nearest hospital.</p><p>These are very serious side effects and are usually very rare. You may need urgent medical attention or hospitalization.</p><ul><li>yellowing of the skin or eyes, also called jaundice, and/or pale stools and dark urine</li><li>vomiting blood or passing bloody or black, tarry stools</li><li>angina.</li></ul><p>Other side effects not listed above may occur in some patients.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine where children cannot reach it.</p><p>- A locked cupboard at least one-and- a-half metres above the ground is a good place to store medicines.</p><p>- Keep your medicine in its original packaging until it is time to take it.</p><p>- If you take your medicine out of its original packaging it may not keep well.</p><p>- Keep your medicine in a cool dry place where the temperature will stay below 30&deg;C. Protect it from moisture.</p><p>- Do not store your medicine, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.</p><p>- If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Claz MR 30mg:</strong></p><p>Each tablet contains 30 mg of gliclazide as the active ingredient.</p><p>&nbsp;</p><p><strong>Claz MR 60mg:</strong></p><p>Each tablet contains 60 mg of gliclazide as the active ingredient.</p><p>&nbsp;</p><p>It also contains the following inactive ingredients:</p><p>Claz MR 30 mg tablets contain:&nbsp; colloidal silicon dioxide, hydroxypropyl methylcellulose and stearic acid.</p><p>Claz MR&nbsp; 60 mg tablets contain:&nbsp; colloidal silicon dioxide, hypromellose, lactose and stearic acid.</p><p>This medicine is gluten-free, lactose- free, sucrose-free, tartrazine-free and free of other azo dyes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Claz MR 30mg:
White to off-white. Flat faced, radial edge, capsule shaped tablet, engraved "APO 30" on one side and plain on the other side.

Claz MR 60mg:
White to off-white. Flat faced, radial edge, capsule shaped tablet, engraved "APO 60" on one side and plain on the other side.

Blister pack of 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Incorporated</p><p>150 Signet Drive</p><p>Toronto, Ontario</p><p>Canada, M9L 1T9</p><p>Tel: 1-800-268-4623, Fax: 1-800-609-9444</p><p>www.apotex.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>أ- كيف يعمل كلاز</strong><strong> MR</strong></p><p dir="RTL">المادة الفعالة في كلاز MR هي الجليكلازايد. ينتمي الجليكلازايد إلى مجموعة من الأدوية تسمى السلفونيل يوريا.</p><p dir="RTL">يقلل الجليكلازايد من ارتفاع السكر في الدم عن طريق زيادة كمية الأنسولين التي ينتجها البنكرياس.</p><p dir="RTL">يستخدم الجلوكوز من قبل الجسم كوقود، وجميع الناس يدور الجلوكوزفي دمائهم.</p><p dir="RTL">يستخدم هذا الدواء للسيطرة، على السكر في الدم في المرضى الذين يعانون من مرض السكري من النوع الثاني.</p><p dir="RTL">يعرف هذا النوع من مرض السكري بداء السكري غير المعتمد على الأنسولين (NIDDM) أو مرض السكري عند بداية النضج.</p><p dir="RTL">ويستخدم كلاز MR عندما الحمية والتمارين الرياضية وحدها لا تكفي للسيطرة على نسبة الجلوكوز في الدم.</p><p dir="RTL">ويمكن استخدام كلاز MR وحده، أو مع غيرها من الأدوية لعلاج مرض السكري</p><p dir="RTL">اسأل طبيبك إذا كان لديك أي أسئلة حول لماذا تم وصف هذا الدواء لك. ربما يكون طبيبك قد وصف لك هذا الدواء لسبب آخر.</p><p dir="RTL">هذا الدواء يتوفر فقط مع وصفة طبيب.</p><p dir="RTL">في مرض السكري، تكون مستويات السكر في الدم أعلى من المطلوب. وهذا ما يسمى فرط سكر الدم.</p><p dir="RTL">وهناك قسم في نهاية هذه النشرة يحتوي على نصائح حول التعرف على ومعالجة فرط سكر الدم.</p><p dir="RTL">من المهم جدا السيطرة على ارتفاع السكر في الدم سواء أشعرت أم لم تشعر بتوعك. لأن هذا في الواقع يساعد على تجنب المشاكل الصحية الخطيرة على المدى الطويل، والتي يمكن أن تصيب القلب والعينين، والدورة الدموية، و / أو الكليتين.</p><p dir="RTL">كما هو الحال مع العديد من الأدوية المستخدمة لعلاج مرض السكري، هناك احتمال أن تصبح مستويات السكر في الدم منخفضة جدا خلال فترة العلاج بكلاز MR. وهذا هو ما يعرف باسم نقص سكر الدم.</p><p dir="RTL">وهناك قسم في نهاية هذه النشرة يحتوي على نصائح حول التعرف على ومعالجة نقص سكر الدم.</p><p dir="RTL">لا يوجد أي دليل على أن هذا الدواء يسبب الادمان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب- استخدامه مع الاطفال</strong></p><p dir="RTL">هذا الدواء لا ينبغي أن يستخدم في الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ- متى يجب عدم استخدام كلاز</strong><strong> MR</strong></p><p dir="RTL">لا تتناول هذا الدواء في الحالات التالية:</p><ul dir="rtl"><li>إذا مر تاريخ انتهاء (EXP) المطبوع على العبوة.</li><li>إذا تمزق التغليف، أو ظهرت علامات للتلاعب أو لم يبدو صحيحا تماما.</li><li>إذا كان لديك مرض السكري من النوع الأول (داء السكري المعتمد على الانسولين، والمعروف أيضا بـIDDM، أو سكري الصغار أو سكر بداية النمو)</li><li>إذا كان لديك السكري الغير مستقر أو الهش</li><li>إذا كان لديك الحماض السكري</li><li>إذا كان لديك غيبوبة السكري أو ما قبل الغيبوبة،</li><li>إذا كان لديك تاريخ مسبق للتعرض للحماض الكيتوني المتكرر أو الغيبوبة</li><li>إذا كان لديك أمراض الكلى الحادة</li><li>إذا كان لديك أمراض الكبد الحادة</li><li>إذا كنت تستخدم ميكونازول لعلاج الالتهابات الفطرية.</li><li>إذا كنت تتناول أدوية تسمى فينايل بيوتازون أو دانازول.</li><li>إذا كان لديك رد فعل تحسسي لـ:<ul><li>الكلاز MR أو غيره من السلفونيل يوريا</li><li>المضادات الحيوية التي تدعى السلفوناميدات</li><li>مدرات البول الثيازيدية (وهي نوع من أقراص &quot;السوائل&quot; أو أقراص &quot;المياه&quot;)</li><li>أي من العناصر المدرجة في نهاية هذه النشرة.</li></ul></li></ul><p dir="RTL">قد تشمل أعراض الحساسية السعال، وضيق في التنفس، والأزيز أو صعوبة في التنفس، تورم في الوجه، والشفتين، واللسان، والحلق أو أجزاء أخرى من الجسم، والطفح الجلدي، والحكة، أو بقع على الجلد؛ إغماء أو أعراض تشبه أعراض حمى القش.</p><p dir="RTL">إذا كنت تعتقد أنك تعاني من الحساسية، لا تتناول الدواء بعد ذلك وقم بالاتصال بالطبيب على الفور أو اتجه إلى قسم الحوادث والطوارئ في أقرب مستشفى.</p><p dir="RTL">يمكن لأعراض الحساسية أن تشتمل على بعض أو كل ما يلي:</p><ul dir="rtl"><li>السعال وضيق في التنفس، صفير أو صعوبة في التنفس.</li><li>تورم في الوجه والشفتين واللسان والحلق أو أجزاء أخرى من الجسم</li><li>طفح جلدي حاد، والحكة أو بقع تحسسية على الجلد</li><li>إغماء</li><li>أعراض تشبه اعراض حمى القش</li><li>&nbsp;</li></ul><p dir="RTL"><strong>ب- الحمل والرضاعة</strong></p><ul dir="rtl"><li>إذا كنتِ حاملا أو تخططين لتصبحي حاملا. قد يؤثر كلاز MR على تطور نمو الجنين إذا تم تناوله أثناء الحمل. عادة ما يقوم طبيبك باستبدال كلاز MR بالانسولين أثناء فترة حملك.</li><li>إذا كنتِ تمارسين الرضاعة الطبيعية أو تخططين لإرضاع طفلك رضاعة طبيعية. ليس من المعروف ما إذا كان كلاز MR يفرز في حليب الثدي البشري أم لا. لا تتناولي هذا الدواء أثناء ممارسة الرضاعة من الثدي حتى تناقشي مع طبيبك المخاطر والمنافع المشتركة.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>ت- الاحتياطات عند استعمال</strong></p><p dir="RTL">تذكر أن تداوم على فحص مستويات الجلوكوز في الدم.</p><p dir="RTL">قبل البدء في تناول هذا الدواء، أخبر طبيبك إذا:</p><ul dir="rtl"><li>كان لديك حساسية من أي أدوية أخرى أو أي مواد أخرى، مثل المواد الحافظة، والأطعمة أو الأصباغ.</li><li>كان لديك أو مازال لديك أي ظرف من الظروف الطبية، لا سيما ما يلي:<ul><li>مشاكل في الكلى</li><li>مشاكل في الكبد</li><li>ورم في البنكرياس لديك، ويدعى الورم الجزيري</li><li>تاريخ مسبق للتعرض لغيبوبة السكري.</li><li>مشاكل في الغدة الكظرية، والغدة النخامية أو مشاكل في الغدة الدرقية.</li><li>فشل القلب</li><li>حالة تسمى نقص الجلوكوز 6 فوسفات (G6PD)</li></ul></li><li>كان لديك أي حالة طبية، أو قمت بعمل أي شيء، والذي قد يزيد من خطر حدوث فرط سكر الدم - على سبيل المثال:<ul><li>كنت مريضا أو شعرت بالتعب (وخصوصا مع حمى أو عدوى).</li><li>كنت مصابا بجروح.</li><li>كنت قد خضعت لعملية جراحية.</li><li>كنت تتناول كلاز MR أقل مما وصف الطبيب لك.</li><li>تقوم بممارسة التمارين بشكل أقل من المعتاد.</li><li>كنت تتناول المزيد من الكربوهيدرات أكثر من المعتاد.</li></ul></li><li>كنت تتناول دواء يسمى حاصرات البيتا. إن تناول هذا النوع من الأدوية قد يحجب عنك الشعور بأعراض مرض السكري.</li><li>كان لديك أي حالة طبية، أو قمت بعمل أي شيء، والذي قد يزيد من مخاطر نقص سكر الدم - على سبيل المثال:<ul><li>تناول المشروبات الكحولية.</li><li>عدم تناول وجبات منتظمة، بما في ذلك وجبة الإفطار.</li><li>القيام بمارسة المزيد من التمارين الرياضية أكثر من المعتاد</li><li>تناول كميات أقل من الكربوهيدرات عن المعتاد.</li></ul></li><li>الكحول، والنظام الغذائي، وممارسة الرياضة، والصحة العامة الخاصة بك تؤثر بشكل كبير على إمكانية السيطرة على مرض السكري لديك.</li><li>لا تتناول وجبات منتظمة من الطعام</li><li>كنت تتناول أو تخطط لتناول أي أدوية أخرى.</li><li>وتشمل هذه الفيتامينات والمدعمات الغذائية التي تتوفر في الصيدلية، أو السوبر ماركت أو متجر الأطعمة الصحية.</li><li>إذا كنت مسافرا، فمن االمستحسن:<ul><li>ارتداء بعض أشكال تحديد الهوية والتي تظهرأن لديك مرض السكري</li><li>أن تحمل نوعا من السكر لعلاج نقص سكر الدم (انخفاض نسبة السكر في الدم) إذا حدث ذلك، على سبيل المثال، كيس السكر أو حبيبات الجل</li><li>أن تحمل معونات غذائية طارئة في حالة وجود تأخر في الرحلة، على سبيل المثال، الفواكه المجففة، والبسكويت أو أشرطة مزيج منهما</li><li>إبقاء أقراص كلاز MR متاحة للتناول بسهولة.</li></ul></li></ul><p dir="RTL">إذا أصبحت مريضا بحمى وبرد أو انفلونزا، فمن المهم جدا أن تستمر بتناول كلاز MR، حتى لو كنت تشعر بأنك غير قادر على تناول وجبتك العادية.</p><p dir="RTL">إذا كان لديك مشكلة في تناول الطعام الصلب، فاستخدم المشروبات المحلاة بالسكر كبديل للكربوهيدرات أو تناول كميات قليلة من المواد الغذائية اللطيفة.</p><p dir="RTL">وبإمكان مرشد السكري الخاص بك أو اختصاصي التغذية أعطاؤك قائمة من المواد الغذائية لاستخدامها أيام المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ث- تأثير على القيادة واستخدام الآلات</strong></p><p dir="RTL">كن حذرا تجاه القيادة أو تشغيل الآلات حتى تعرف كيفية تأثير كلاز MR عليك.</p><p dir="RTL">قد يسبب كلاز MR دوخة ونعاس في بعض الناس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد شرب الكحول الأمور سوءاً. إذا كنت تشعر بالدوار أو النعاس، لا تقد السيارة، ولا تقم بتشغيل الآلات أو عمل أي شيء آخر قد يكون خطرا.</p><p dir="RTL">كن حريصا بعدم السماح لمستويات الجلوكوز في الدم بالإنخفاض الشديد.</p><p dir="RTL">إن انخفاض مستويات السكر في الدم قد تؤدي إلى بطء رد فعلك وتؤثر على القدرة على قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL">هناك قسم في نهاية هذه النشرة يحتوي على نصائح حول التعرف على ومعالجة نقص سكر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج- التفاعلات مع هذا الدواء</strong></p><ul dir="rtl"><li>بعض الأدوية قد تتفاعل مع كلاز MR. وهذه تشمل:</li><li>الأدوية الأخرى المستخدمة لعلاج مرضى السكري (الأقراص والانسولين)</li><li>بعض الأدوية المستخدمة لعلاج ارتفاع ضغط الدم وأمراض القلب الأخرى، مثل حاصرات بيتا، مثبطات الآيس.</li><li>بعض الهرمونات المستخدمة في العلاج بالهرمونات البديلة وحبوب منع الحمل (الاستروجين والمركبات البروجستيرونية المفعول)</li><li>مثبطات مؤكسدات أحادي الأمين (MAOIs)، وتستخدم لعلاج الاكتئاب، ومرض باركنسون أو العدوى</li><li>بعض الأدوية المستخدمة لمرض عقلي (مثل الكلوربرومازين)</li><li>بعض الأدوية المستخدمة لعلاج الصرع مثل فينوباربيتون</li><li>كلوفيبرات، وهو دواء لخفض الكولسترول</li><li>الأدوية المستخدمة لعلاج التهاب المفاصل، والألم والالتهاب (مثل الأوكسي فينبوتازون، فينايل بيوتازون، جرعة عالية من الساليسيلات)</li><li>المضادات الحيوية التي تدعى سلفوناميدات، أو الكلورامفينيكول</li><li>ميكونازول، أو فلوكونازول، وتستخدم لعلاج الالتهابات الفطرية</li><li>بعض الأدوية المستخدمة لمنع تجلط الدم (الوارفارين والأدوية المماثلة)</li><li>السيميتيدين والأدوية المماثلة المستخدمة لعلاج الإرتجاع الحمضي وقرحة المعدة</li><li>الأدوية الستيرويدية والتي تدعى الجلوكوكورتيكوستيرويدات (مثل البريدنيزولون، الكورتيزون)</li><li>بعض أدوية لعلاج الاضطرابات الهرمونية (مثل دانازول)</li><li>السالبوتامول وتيربوتالين، وهي أدوية لعلاج الربو</li><li>مدرات البول، التي تعرف أيضا باسم أقراص السوائل (على سبيل المثال كلوروثيازيد)</li><li>إذا كنت تتناول أي من هذه الأدوية فقد تحتاج إلى جرعة مختلفة أو قد تحتاج إلى تناول أدوية مختلفة. قد تكون هناك أدوية أخرى غير المذكورة أعلاه قابلة للتفاعل مع كلاز MR .</li></ul><p dir="RTL">إن شرب الكحول يؤثر أيضا على مستويات السكر في الدم وعلى جودة عمل كلاز MR. إذا&nbsp; تم تناوله مع كلاز MR ، فإنه قد يسبب أيضا توهج في الوجه، الصداع النابض، والدوخة، وسرعة التنفس، سرعة دقات القلب، والذبحة الصدرية، أو آلام في المعدة وغثيان أو تقيؤ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع بعناية جميع الإرشادات الموجهة لك من قبل الطبيب أو الصيدلي أو مرشد السكري.</p><p dir="RTL">قد تكون تعليماتهم مختلفة عن المعلومات الواردة في هذه النشرة.</p><p dir="RTL">تفرز الأقراص مادة الكلاز MR&nbsp; تدريجيا على مدى 24 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ- ماهو المطلوب استخدامه من كلاز</strong><strong> MR</strong></p><p dir="RTL">سيخبرك الطبيب أو الصيدلي بالكمية التي عليك تناولها من هذا الدواء. وهذا يعتمد على حالتك وعلى ما إذا كنت تتناول أي أدوية أخرى.</p><p dir="RTL">الجرعة الإبتدائية عادة هي 30 ملجم يوميا (نصف قرص من كلاز MR60 ملغم أو قرص كامل من كلاز MR 30 ملغم). وسيتم تعديلها ببطء على مدى عدة أسابيع، وهذا يتوقف على مدى استجابة جسمك للجرعة.</p><p dir="RTL">قد تختلف الجرعة المعتادة من هذا الدواء من حبة إلى 4 حبات كل يوم.</p><p dir="RTL">قد يزيد لك طبيبك أو قد ينقص لك الجرعة، اعتمادا على مستويات الجلوكوز في الدم.</p><p dir="RTL">لا تتوقف عن تناول الدواء ولا تقم بتغيير الجرعة دون التحقق أولا من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب- كيف يستخدم كلاز</strong><strong> MR </strong><strong>ومتى</strong></p><p dir="RTL">قم بابتلاع الاقراص كاملة مع كوب من الماء. لا تسحق الأقراص أو تكسرها.</p><p dir="RTL">تناوله في الوقت نفسه تقريبا كل يوم، وعادة مع وجبة الإفطار.</p><p dir="RTL">إن تناول هذه الأقراص مع الطعام يساعد على تقليل مخاطر نقص سكر الدم.</p><p dir="RTL">سوف يساعدك أيضا على تذكر موعد تناولها.</p><p dir="RTL">لا تترك وجبات الطعام في حين تناول هذه الاقراص.</p><p dir="RTL">يمكن أن يساعد الكلاز MR في السيطرة على مستوى الجلوكوز في دمك، ولكنه لا يستطيع علاج السكري من النوع 2.</p><p dir="RTL">العلاج بكلاز MR عادة ما يكون لفترة طويلة من الزمن - لذلك يجب أن تتناول الأقراص بانتظام ما لم ينصحك الطبيب بخلاف ذلك.</p><p dir="RTL">تأكد أن لديك ما يكفيك من الدواء خلال عطلة نهاية الأسبوع والأعياد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ت- الجرعة الزائدة</strong></p><p dir="RTL">إذا كنت تعتقد أنك أو أي شخص آخر قد تناول الكثير من هذا الدواء، فاتصل وفورا بطبيبك أو بمركز معلومات السموم للحصول على المشورة. أو اذهب بدلا من ذلك إلى قسم الحوادث والطوارئ في أقرب مستشفى لديك.</p><p dir="RTL">قم بذلك حتى لو لم تكن هناك أي علامات للانزعاج أو التسمم. فقد تحتاج إلى عناية طبية عاجلة.</p><p dir="RTL">إذا كنت تتناول الكثير من كلاز MR فقد تشعر بأعراض نقص سكر الدم (انخفاض نسبة السكر في الدم).</p><p dir="RTL">إذا لم تعالج بسرعة، فإن هذه الأعراض قد تتطور إلى أن يصاب الشخص بفقدان التنسيق، الكلام المبهم، والارتباك، وفقدان الوعي والتشنجات.</p><p dir="RTL">عند ظهور أول علامات نقص سكر الدم (انخفاض نسبة السكر في الدم)، قم برفع نسبة الجلوكوز في الدم بسرعة عن طريق تناول حبيبات الجل، السكر أو العسل، (غير مواد الحمية) المشروبات الغازية أو أقراص الجلوكوز.</p><p dir="RTL">لاحظ أن المحليات الاصطناعية لن تساعد على رفع مستويات السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ث- الجرعة الفائتة</strong></p><p dir="RTL">تناول الجرعة المقررة التالية في الوقت المعتاد واستمر كالمعتاد.</p><p dir="RTL">لا تأخذ جرعة مضاعفة لتعويض الجرعة التي فاتك.</p><p dir="RTL">اذا ضاعفت الجرعة، فقد يسبب ذلك نقص سكر الدم (انخفاض نسبة السكر في الدم).</p><p dir="RTL">إذا كنت غير متأكد مما يجب القيام به، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">إذا كان لديك صعوبة في تذكر وقت تناول الدواء، فاسأل الصيدلي عن بعض التلميحات لمساعدتك على التذكر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج- عند استخدام كلاز</strong><strong> MR</strong></p><p dir="RTL">تناول أقراصك تماما كما وصف لك طبيبك.</p><p dir="RTL">وإلا فإنك لن تحصل على الفوائد الكاملة من العلاج.</p><p dir="RTL">تأكد من فحصك لمستويات الجلوكوز في دمك بانتظام. فهذه هي أفضل وسيلة لمعرفة ما إذا تمت السيطرة على داء السكري بشكل صحيح. سيقوم الطبيب أو مرشد السكري بالتوضيح لك كيف ومتى يجب عليك القيام بذلك.</p><p dir="RTL">تأكد من أنك، أصدقاؤك، وأفراد أسرتك وزملاء عملك يمكنكم التعرف على أعراض نقص سكر الدم (انخفاض نسبة السكر في الدم)، وفرط سكر الدم (ارتفاع مستوى السكر في الدم)، ومعرفة ماذا يجب عمله في الحالتين.</p><p dir="RTL">يمكنك الإستعانة بالتعليمات المذكورة في نهاية هذه النشرة.</p><p dir="RTL">قم بزيارة الطبيب لاجراء فحوص منتظمة للدم ولفحص عينيك والقدمين والكلى والقلب والدورة الدموية، والدم، وضغط الدم.</p><p dir="RTL">اتبع بعناية نصيحة الطبيب واختصاصي التغذية بشأن النظام الغذائي، وشرب الكحول وممارسة الرياضة.</p><p dir="RTL">أخبر طبيبك فورا إذا لاحظت عودة أي من أعراض فرط سكر الدم والتي كنت تعاني منها قبل تناولك لكلاز MR، أو إذا كانت مستويات السكر في الدم لديك مرتفعة.</p><p dir="RTL">قد تكون هذه علامات على أن كلاز MR لم يعد يعمل، حتى ولو كنت تتناول الدواء بصورة ناجحة لبعض الوقت.</p><p dir="RTL">إذا كنت من كبار السن أو تتناول أدوية أخرى لمرض السكري مثل ميتفورمين أو الأنسولين، فإن خطورة التعرض لنقص سكر الدم (انخفاض نسبة السكر في الدم) تزداد.</p><p dir="RTL">إن إمكانية التعرض لخطر نقص سكر الدم (انخفاض نسبة السكر في الدم) تزيد أيضا في الحالات التالية:</p><ul dir="rtl"><li>تناول الكثير من كلاز MR</li><li>ممارسة الرياضة أكثر من اللازم أو القيام بتمارين غير متوقعة</li><li>تأخير تناول وجبة طعام رئيسية أو وجبة خفيفة</li><li>طعام قليل جدا.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تواجه أي من علامات ارتفاع السكر في الدم (فرط سكر الدم)، فاتصل بطبيبك على الفور.</p><p dir="RTL">ويزداد خطر فرط سكر الدم (ارتفاع مستوى السكر في الدم) في الحالات التالية:</p><ul dir="rtl"><li>داء السكري الذي لم يتم تشخيصة أو غير المنضبط</li><li>المرض والتعب أو الإجهاد</li><li>تناول القليل جدا من الكلاز MR</li><li>تناول بعض الأدوية الأخرى</li><li>ممارسة القليل جدا من التمارين الرياضية</li><li>تناول المزيد من الكربوهيدرات أكثر من المعتاد.</li></ul><p dir="RTL">إذا أصبحت مريضا أو عانيت من توتر إضافي، أو تعرضت لإصابة، حمى، عدوى أو كنت بحاجة للخضوع لعملية جراحية، فأخبر طبيبك.</p><p dir="RTL">قد يصبح من الصعب السيطرة على نسبة الجلوكوز في الدم لديك في هذه الأوقات. لذلك فقد يقرر طبيبك تغيير العلاج واستخدام الانسولين بدلا من كلاز MR</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دـ- التعرف على ومعالجة نقص سكر الدم (الإنخفاض الشديد في مستويات السكر في الدم)</strong></p><p dir="RTL">قد يحدث نقص سكر الدم خلال فترة العلاج بكلاز MR .</p><p dir="RTL">أول علامات نقص سكر الدم يمكن أن تشمل الضعف، والرجفة أو الرعشة، والتعرق، والقلق، والتغيرات في معدل ضربات القلب والتنفس، والشعور بخفة الرأس، والدوخة، ومشاكل في النظر، صداع، أو عدم القدرة على التركيز، التهيج، الاكتئاب، العدوان، البكاء، الجوع، الغثيان القيء وألم في الصدر و / أو خدر حول الشفتين واللسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويمكن لهذه الأعراض أن تحدث فجأة.</p><p dir="RTL">إذا لم تعالج بسرعة، فقد تتطور إلى:</p><ul dir="rtl"><li>فقدان التنسيق</li><li>ثقل اللسان</li><li>الارتباك، والنعاس</li><li>فقدان الوعي أو التشنجات.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">في أول علامات نقص سكر الدم تناول بعض السكر لرفع مستوى السكر في الدم بسرعة.</p><p dir="RTL">قم بذلك عن طريق تناول أحد المواد التالية:</p><ul dir="rtl"><li>5-7 من حبيبات الجل</li><li>3 ملاعق صغيرة من السكر أو العسل</li><li>&bull;نصف علبة عادية (غير الحمية) من المشروبات الغازية</li><li>2-3 من أقراص الجلوكوز المركزة</li><li>أنبوب من جل الجلوكوز</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لاحظ أن تناول المحليات الاصطناعية لن يساعد على رفع مستويات السكر في الدم.</p><p dir="RTL">ثم تناول بعض الكربوهيدرات الاضافية مثل البسكويت السادة، الفواكه أو الحليب - إلا إذا كان الوقت المتبقي على وجبة طعامك المقبلة 10-15 دقيقة.</p><p dir="RTL">إن تناول هذه الكربوهيدرات الاضافية سوف يساعد على منع انخفاض مستوى السكر في الدم لديك مرة أخرى.</p><p dir="RTL">إذا لم تتحسن أعراض نقص سكر الدم على الفور بعد تناول السكر، أو إزدادت شدة الأعراض أو استمرت لفترات طويلة، فعليك التوجه إلى قسم الحوادث والطوارئ في أقرب مستشفى لديك - وإذا لزم الأمر قم باستدعاء سيارة اسعاف.</p><p dir="RTL">اتصل بطبيبك أو مرشد السكري للحصول على المشورة إذا كنت تشعر بالقلق إزاء نقص سكر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ- التعرف على ومعالجة زيادة سكر الدم (ارتفاع في مستويات السكر في الدم</strong><strong>)</strong></p><p dir="RTL">قد يشعر بعض الناس أنهم على ما يرام عندما تكون مستويات الجلوكوز لديهم مرتفعة.</p><p dir="RTL">يحدث ارتفاع السكر في الدم عادة ببطء أكثر من انخفاض السكر في الدم. ومن علامات ارتفاع السكر في الدم ما يلي:</p><ul dir="rtl"><li>الخمول أو التعب</li><li>الصداع</li><li>العطش</li><li>طرح كميات كبيرة من البول</li><li>عدم وضوح الرؤية.</li></ul><p dir="RTL">إذا لاحظت أعراض فرط سكر الدم، أو كانت مستويات السكر في دمك مرتفعة، فعليك إخبار الطبيب فورا. قد تحتاج تعديلات على الجرعة أو تغيير نوع من الأدوية التي تتناولها.</p><p dir="RTL">من المهم جدا السيطرة على ارتفاع السكر في الدم سواء شعرت أم لم تشعر بتوعك. لأن هذا في الواقع يساعد على تجنب المشاكل الصحية الخطيرة على المدى الطويل، والتي يمكن أن تصيب القلب والعينين، والدورة الدموية، و / أو الكلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إخبر الطبيب والصيدلي، أو مرشد السكري بأسرع وقت ممكن إذا كنت تشعر بتوعك أثناء تناولك للكلاز MR أو إذا كان لديك أي أسئلة أو استفسارات أخرى.</p><p dir="RTL">لا تندهش من القوائم التالية بخصوص الآثار الجانبية. قد لا تواجه أي منها. جميع الأدوية لها آثار جانبية. أحيانا تكون خطيرة ولكن في معظم الوقت هي ليست كذلك.</p><p dir="RTL">اخبر الطبيب أو الصيدلي إذا لاحظت أي من الحالات التالية والتي قد تقلقك.</p><p dir="RTL">تتضمن هذه القائمة الآثار الجانبية الأكثر شيوعا. وفي الغالب، تكون خفيفة:</p><ul dir="rtl"><li>اضطراب المعدة بما في ذلك الغثيان والقيء (الشعور بالغثيان)، حرقة المعدة، الإسهال، والإمساك أو الشعور بالامتلاء في المعدة</li><li>مشاكل البصر (وهذا قد يحدث فقط عند بدء تناول ومع التغير في مستويات السكر في الدم لديك)</li><li>ضجر</li><li>دوخة أو الدوار</li><li>الصداع</li><li>طفح جلدي معتدل أو احمرار في الجلد.</li></ul><p dir="RTL">أخبر طبيبك في أقرب فرصة ممكنة إذا لاحظت ظهور أي مما يلي.</p><p dir="RTL">قد تكون هذه آثار جانبية خطيرة. قد تحتاج إلى عناية طبية. معظم هذه الآثار الجانبية نادرة.</p><ul dir="rtl"><li>نقص سكر الدم أو فرط سكر الدم. وهناك قسم في نهاية هذه النشرة يحتوي على نصائح حول التعرف على ومعالجة نقص سكر الدم أو فرط سكر الدم.</li><li>علامات العدوى المتكررة أو العدوى المثيرة للقلق مثل الحمى، الرعشة الشديدة، التهاب في الحلق أو تقرحات الفم</li><li>علامات فقر الدم مثل التعب، الشعور بضيق في التنفس والشحوب</li><li>نزيف أو حدوث الكدمات بسهولة أكثر من الطبيعي، بقع محمرة أو أرجوانية تحت الجلد</li><li>حكة، واحمرار العروق الدموية.</li></ul><p dir="RTL">إذا واجهت أي من الأمور التالية، توقف عن تناول الدواء واتصل بطبيبك على الفور أو اذهب إلى قسم الحوادث والطوارئ في أقرب مستشفى لديك.</p><p dir="RTL">هذه آثار جانبية خطيرة للغاية، وعادة ما تكون نادرة جدا. قد تحتاج إلى عناية طبية عاجلة أو تنويم بالمستشفى.</p><ul dir="rtl"><li>اصفرار الجلد أو العينين، ويسمى أيضا واليرقان، و / أو براز شاحب وبول الداكن.</li><li>تقيؤ الدم أو أخراج براز دموي أو أسود، أو قاري</li><li>الذبحة الصدرية.</li></ul><p dir="RTL">هناك آثار جانبية أخرى غير مذكورة أعلاه قد تحدث في بعض المرضى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>يحفظ&nbsp; بعيدًا عن متناول الأطفال.</li><li>تعتبر الخزانة مقفلة التي ترتفع عن الأرض على الأقل بمتر واحد ونصف مكاناً جيد لتخزين الأدوية.</li><li>احفظ الدواء في عبوته الأصلية حتى يحين وقت تناوله.</li><li>إذا&nbsp;أخرجت الدواء من عبوته الأصلية فقد لا تستطيع المحافظة عليه.</li><li>احفظ الدواء في مكان بارد وجاف حيث تكون درجة الحرارة أقل من 30 درجة مئوية. أحفظه بعيدا عن الرطوبة.</li><li>لا تخزن الأدوية الخاصة بك، أو أي دواء آخر، في الحمام أو بالقرب من المغسلة. لا تتركه على عتبة النافذة أو في السيارة. يمكن للحرارة والرطوبة أن تتلف بعض الأدوية.</li><li>إذا أخبرك الطبيب او الصيدلي بالتوقف عن تناول هذا الدواء أو إذا تجاوز تاريخ انتهاء الصلاحيه، فيمكن للصيدلي التخلص من الدواء المتبقي بسلام.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ- المكونات الطبية</strong></p><p dir="RTL"><strong>كلاز 30 MR&nbsp;</strong><strong>ملغم: </strong></p><p dir="RTL">كل قرص يحتوي على 30 ملجم من جليكلازايد كمادة فعالة.</p><p dir="RTL"><strong>كلاز </strong><strong>&nbsp;MR&nbsp;</strong><strong>60 ملغم:</strong></p><p dir="RTL">كل قرص يحتوي على 60 ملجم من جليكلازايد كمادة فعالة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب- المكونات غير الطبية</strong></p><p dir="RTL">كما أنه يحتوي على العناصر التالية الغير نشطة:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;أقراص كلاز </strong><strong>&nbsp;MR&nbsp;</strong><strong>30 ملغم تحتوي علي : </strong>السيليكا الغروية اللامائية، هيدروكسي بروبيل ميثيل سيليولوز و حامض دهني.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أقراص كلاز </strong><strong>&nbsp;MR&nbsp;</strong><strong>60 ملغم تحتوي علي: </strong>السيليكا الغروية اللامائية، هايبرميللوز، اللاكتوز و حامض دهني.</p><p>&nbsp;</p><p dir="RTL">هذا الدواء خال من الغلوتين، خالي من اللاكتوز، خالي من السكروز، خالي من التارتازين وخالي من أصباغ آيزو الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كلاز </strong><strong>&nbsp;MR</strong><strong>30 ملغم:</strong></p><p dir="RTL">أقراص كبسولية الشكل بيضاء إلى أبيض مصفر قليلا، ذات أوجه مسطحة، غير مشطوفة الحافة، محفور عليها&nbsp; &quot;APO 30&quot; من جهة، وسليمة من الجهة الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كلاز </strong><strong>&nbsp;MR&nbsp;</strong><strong>60 ملغم:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص كبسولية الشكل بيضاء إلى أبيض مصفر قليلا، ذات أوجه مسطحة، غير مشطوفة الحافة، محفور عليها&nbsp; &quot;APO 60&quot; من جهة، وسليمة من الجهة الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">علبة اشرطة من 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة أبوتكس إنك</p><p dir="RTL">150 سيجنت درايف</p><p dir="RTL">تورنتو، أونتاريو&nbsp;&nbsp;9 M9L 1T</p><p dir="RTL">ت:18002684623 ، ف: 18006099444</p><p dir="RTL">www.apotex.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name in the GCC States: Claz MR
Trade Name in the Country of Origin: Apo-Gliclazide MR Tablets
Generic Name: Gliclazide
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Modified-release tablet 30 mg	:
Colloidal silicon dioxide, hydroxypropyl methylcellulose and stearic acid.

Modified-release breakable tablet 60 mg:
Colloidal silicon dioxide, hypromellose, lactose and stearic acid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CLAZ MR 30 mg tablets: White, to off-white, flat-faced, radial edge, capsule shaped tablets, engraved “30” on one side and plain on the other side.

CLAZ MR 60 mg tablets: Each white to off-white, oval shaped biconvex tablets. Engraved “GL” bisect “60” on one side, “APO” bisect “APO” on the other side contains 60 mg gliclazide.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.</p><p>&nbsp;</p><p><strong>Geriatrics</strong><strong> </strong><strong>(&ge; 65 years of age):</strong></p><p>No significant differences in efficacy and tolerance were observed between patients over 65 years of age and younger patients, however greater sensitivity of some older individuals cannot be ruled out.</p><p>&nbsp;</p><p><strong>Pediatrics</strong><strong> </strong><strong>(&lt;</strong><strong> </strong><strong>18</strong><strong> </strong><strong>years</strong><strong> </strong><strong>of</strong><strong> </strong><strong>age):</strong></p><p>Safety and effectiveness of Gliclazide modified release tablets in children have not been established. Gliclazide modified release tablets is therefore not recommended for use in children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dosing</strong><strong> </strong><strong>Considerations</strong></p><p>Determination of the proper dosage for CLAZ MR for each patient should be made on the basis of frequent determinations of blood glucose during dose titration and throughout maintenance.</p><p>The daily dose of CLAZ MR may vary from 30 to 120 mg once daily (i.e., one half tablet to 2 tablets of CLAZ MR 60 mg, or 1 to 4 tablets of CLAZ MR 30 mg).</p><p>&nbsp;</p><p><strong>Recommended</strong><strong> </strong><strong>Dose</strong><strong> </strong><strong>and Dosage Adjustment</strong></p><p>The recommended starting dose of CLAZ MR is 30 mg daily, i.e. one half tablet of CLAZ MR 60 mg or one tablet of CLAZ MR 30 mg, even in elderly patients (over 65 years old).</p><p>A single daily dose provides effective blood glucose control. The single daily dose may be between 30 mg and 90 mg, or even 120 mg. The daily dose should not exceed 120 mg.</p><p>Dose adjustment should be carried out in steps of 30 mg, according to the blood glucose response. Each step should last for at least two weeks.</p><p>&nbsp;</p><p><strong>Missed</strong><strong> </strong><strong>Dose</strong></p><p>If a dose is forgotten, the patient should be advised to skip the missed dose and take his or her usual dose at the regular time the next day. The dose taken on the next day should not be increased to account for the missed dose.</p><p>&nbsp;</p><p><strong>Administration</strong></p><p>It is recommended that the medication be taken at breakfast time. The 30 mg tablets cannot be split in half and should be swallowed whole. The 60 mg tablets can be halved. Both the 30 mg and 60 mg tablets must not be chewed or crushed.</p><ul><li>Previously untreated patients should commence with a dose of 30 mg and will benefit from dose adjustment until the appropriate dose is reached.</li><li>One CLAZ MR 60 mg tablet is equivalent to two CLAZ MR 30 mg tablets. The breakability of the CLAZ MR 60 mg tablet allows the use of a dose of 30 mg as a half tablet and of 90 mg as one and a half tablets.</li><li>CLAZ MR can replace an antidiabetic treatment without any transitional period.</li></ul><p>If a patient is switched from a hypoglycemic sulfonylurea with a prolonged half-life (i.e. chlorpropamide) he/she should be carefully monitored (for 1 to 2 weeks) in order to avoid hypoglycemia due to possible residual effects of the previous therapy</p><p>&nbsp;</p><p><strong>Geriatrics</strong></p><p>No significant differences in efficacy and tolerance were observed between patients over 65 years of age and younger patients, however greater sensitivity of some older individuals cannot be ruled out. Patients over 65 years of age should be started with 30 mg of Gliclazide modified release tablet with dosage adjustments being made cautiously.</p><p>&nbsp;</p><p><strong>Hepatic or Renal Impairment</strong></p><p>Patients with renal or hepatic impairment should be started with 30 mg of gliclazide with dosage adjustments being made cautiously (see WARNINGS AND PRECAUTIONS - Hypoglycemic reactions).</p><p>&nbsp;</p><p><strong>Patients receiving Insulin</strong></p><p>Maturity onset diabetics with no ketoacidosis or history of metabolic decompensation and whose insulin requirements are less than 40 units per day may be considered for CLAZ MR therapy after cessation of insulin.</p><p>If a change from insulin to CLAZ MR is contemplated in such a patient, discontinue insulin for a period of 2 or 3 days to determine whether any therapy other than dietary regulation and exercise is needed. During this insulin-free interval, test the patient&#39;s urine at least 3 times daily for glucose and&nbsp;&nbsp;ketone &nbsp;bodies and&nbsp;&nbsp;monitor the &nbsp;results carefully. The appearance &nbsp;of significant ketonuria accompanied by glucosuria within 12 to 24 hours after the withdrawal of insulin, strongly suggests that the patient is ketosis prone, and precludes the change from insulin to sulfonylurea therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CLAZ MR is contraindicated in patients with:
• Known hypersensitivity or allergy to gliclazide, other sulfonylureas, sulfonamides, or to any of the excipients of this product (For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section).
• Unstable and/or insulin-dependent (Type 1) diabetes mellitus, particularly juvenile diabetes, diabetic ketoacidosis, diabetic pre-coma and coma.
• During stress conditions such as serious infection, trauma or surgery.
• In the presence of severe hepatic impairment (see WARNINGS AND PRECAUTIONS).
• In the presence of severe renal impairment (see WARNINGS AND PRECAUTIONS).
• Treatment  with  miconazole  via  systemic  route  or  oromucosal  gel  (see  DRUG INTERACTIONS).
• Pregnancy and lactation (see WARNINGS AND PRECAUTIONS  - Special  Populations, Pregnant Women and Nursing Women).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use of CLAZ MR must be considered as treatment in addition to proper dietary regimen and not as substitute for diet.</p><p>Careful selection of patients is important. It is imperative that there be rigid attention to diet, careful adjustment of dosage and instruction of the patient on hypoglycemic reactions, their recognition, remedies and control as well as regular, thorough medical follow-up.</p><p>Since the effects of oral hypoglycemic agents on the vascular changes and other long-term sequelae of diabetes mellitus are not fully known, patients receiving such drugs must be closely observed for both short-and long-term complications. Periodic assessment of cardiovascular, ophthalmic, renal and hepatic status is advisable.</p><p>CLAZ MR use is not recommended with medications containing alcohol, phenylbutazone (systemic route) and danazol and precautions are required when used with chlorpromazine, glucocorticoids, ritodrine, salbutamol, terbutaline and anticoagulant therapy (see DRUG INTERACTIONS).</p><p>&nbsp;</p><p><strong>Carcinogenesis</strong><strong> </strong><strong>and Mutagenesis</strong></p><p>Acute toxicity</p><p><img alt="" width="540" height="445" src="data:image/png;base64,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" /></p><p>The LD 50 is greater than 3000 mg/kg in the mouse, rat and dog (i.e., 300 times the therapeutic dose) and than 2000 mg/kg in the guinea-pig (i.e. 200 times the therapeutic dose).</p><p>Symptomatology is essentially linked to the hypoglycemic effect of the drug.</p><p><strong>Sub-chronic toxicity:</strong></p><p>-&nbsp; Maximum tolerated dose:</p><p>In the dog, this dose is between 150 and 200 mg/kg by daily administration.</p><p>-&nbsp; Four-week oral toxicity study in the Beagle dog:</p><p>Groups of 4 Beagle dogs (2 males, 2 females) were treated for 30 days with 0, 15, 30, 45 or 90 mg/kg/day. At the dose of 90 mg/kg, 2 animals died as a result of prolonged hypoglycemic coma following 2 weeks of treatment. All others showed normal behavior, with the exception of an increase in the weight of the liver. No evidence was found of any change in biochemical (apart from the fall in blood glucose), hematological and histopathological parameters.</p><p>-&nbsp; Two-month oral toxicity study in the guinea-pig:</p><p>Groups of 10 guinea-pigs (5 males, 5 females), were treated 6 days out of 7 for 2 months with 0, 25, 50 or 100 mg/kg/day. Only male animals in the 50 mg/kg group showed delayed weight gain. All others had normal biochemical, hematological and histopathological results.</p><p><strong>Chronic toxicity:</strong></p><p>-&nbsp; Six-month study in the Sprague-Dawley rat:</p><p>Groups of 20 rats (10 males, 10 females) weighing 300 g, were treated for 6 days out of 7 for 6 months with 0, 25, 100 or 200 mg/kg/day. Seven deaths occured as a result of technical problems. All other animals showed normal behavior and haematological results. From a biochemical standpoint, blood urea decreased significantly in the male rats as did blood glucose in the males of the 100 mg/kg/day group.</p><p>Histological examination showed an increase in the weight of the liver and kidneys in male animals, not accompanied by any histological lesion.</p><p>In a six-month rat study carried out in Japan with higher doses (0, 50, 100, 200, 400 and 800 mg/kg/day) females exhibited greater systemic toxicity when compared with males, suggesting that females may be more sensitive to the product: slight increases in liver enzymes together with slight decreases in erythrocytes counts, hematocrit values and hemoglobin concentrations at doses of 200 mg/kg and higher.</p><p>-&nbsp; Six-month study in the Beagle dog:</p><p>Groups of 6 dogs (3 males, 3 females) were treated daily for 6 months with 0, 15 or 30 mg/kg of gliclazide or 50 mg/kg of tolbutamide.</p><p>From a clinical standpoint:</p><p>-&nbsp; 3 deaths (one at 15 mg/kg, two at 30 mg/kg) in the gliclazide group as a result of hypoglycemic coma;</p><p>-&nbsp; 1 convulsion, 4 cases of severe gastro-intestinal disturbances in the tolbutamide group;</p><p>-&nbsp; weight changes and food consumption were similar with both drugs. From a laboratory standpoint:</p><p>-&nbsp; 40% fall in blood glucose in animals treated with gliclazide;</p><p>-&nbsp; signs of hepatotoxicity in the tolbutamide group. From a histological standpoint:</p><p>-&nbsp; increase in weight of the liver in the 3 deaths of the gliclazide group;</p><p>-&nbsp; increase in the weight of the liver and lesions of toxic hepatitis in 5 animals out of 6 of the tolbutamide group.</p><p>-&nbsp; Twelve-month oral toxicity study in the Beagle dog:</p><p>Groups of 8 dogs (4 males, 4 females) were treated for 12 months with 0, 12 or 24 mg/kg/day of gliclazide.</p><p>Four animals in each group were sacrificed after 90 days.</p><p>-&nbsp; there were no deaths;</p><p>-&nbsp; no evidence of any modification in behavior and body weight;</p><p>-&nbsp; significant fall in blood glucose;</p><p>-&nbsp; fluctuation in certain parameters (liver enzymes, lipid profile, creatinine);</p><p>-&nbsp; at autopsy: swelling of the renal and hepatic parenchyma and at the highest dose a slight increase in the weight of the thyroid and slight decrease in the weight of the pituitary gland.</p><p>-&nbsp; Twelve-month oral toxicity study in the rhesus monkey:</p><p>Groups of 8 rhesus monkeys (4 males, 4 females) were treated daily for 12 months with 0, 20, 60 or 180 mg/kg of gliclazide.</p><p>-&nbsp; no evidence was found of any modification in weight gain nor food consumption;</p><p>-&nbsp; significant fall in blood glucose;</p><p>-&nbsp; irregular rise in some liver enzymes in some animals;</p><p>-&nbsp; no abnormality by histopathological examination. Teratogenicity</p><p>Teratogenicity studies have been carried out in three species: mouse, rat and rabbit.</p><p>-&nbsp; In the CD/SPF mouse (group of 30 females), administration of gliclazide at doses of 0, 50, 250 and 500 mg/kg/day starting from mating and throughout gestation did not modify fertilization and abortion rates and had no apparent teratogenic effect.</p><p>-&nbsp; In the CFY-SPF rat (groups of 20 females), administration of gliclazide at doses of 0, 50, 100 and 200 mg/kg/day from the 6th to the 15th day of gestation did not show any embryotoxic effect.</p><p>-&nbsp; In the SD/SPF rat (groups of 60 females), administration of gliclazide at the doses of 0, 15, 30, 60, 120, 240 and 480 mg/kg/day starting from mating and throughout gestation had no effect on fertilization, gestation, mean number of foetuses or incidence of foetal abnormalities. The number of offspring surviving at 48 hours was decreased in the 15, 60, 120 and 480 mg/kg groups. No other abnormality was seen.</p><p>-&nbsp; In the common rabbit (group of 15 females), administration of gliclazide at doses of 0, 10, 25 and 50 mg/kg/day from the 6th to the 18th day of gestation had no effect on the number of foetal resorptions, percentage of abortion nor the mean number of foetuses per litter.</p><p>-&nbsp; In the New Zealand rabbit (group of 6 females), administration of gliclazide at doses of 0, 50, 75, 100 and 200 mg/kg/day for 13 days followed by an observation period of 8 days, was associated with maternotoxicity and embryotoxicity in the form of gastro-intestinal and renal lesions accompanied by anorexia and weight loss. However, there was no evidence of any teratogenic effect.</p><p><strong>Fertility and reproduction</strong></p><p>In the SD rat, groups of 40 females and of 20 males were treated for 8 and 70 days respectively before mating and until weaning in the females, and until 15 days after littering in the males, with gliclazide at doses of 0, 10, 50 and 200 mg/kg/day.</p><p>There was no evidence of any change in fertilization nor abortion rates. Foetal resorption, placental haemorrhage and foetal atrophy rates were unaffected. The genital tract of treated parents showed no abnormality imputable to treatment. No embryotoxic effect was seen on foetuses of females sacrificed before littering. In females in which gestation was allowed to run to term, a significant decrease in the viability of offspring was seen at 48 hours. No abnormality was seen during the study of fertility and reproduction in first generation offspring born of treated animals.</p><p><strong>Carcinogenicity studies</strong></p><p>Specific carcinogenicity studies have not been performed; the following safety data are now available:</p><p>-&nbsp; gliclazide belongs to the chemical class of the phenylsulfonylurea which did not demonstrate any mutagenic or carcinogenic potential. Its metabolic pathway is consistent with the general metabolic pathway of the class;</p><p>-&nbsp; gliclazide was not associated with any mutagenic action in the numerous studies performed;</p><p>-&nbsp; long term toxicity studies did not reveal any evidence of carcinogenicity;</p><p>-&nbsp; gliclazide has been studied in several thousands of patients during clinical trials and has been marketed for numerous years all over the world and in particular in Europe and Japan without any suspicion of carcinogenicity.</p><p>&nbsp;</p><p><strong>Endocrine<strong> </strong>and Metabolism</strong></p><p><u>Hypoglycemic reactions</u></p><p>As with other sulfonylurea drugs, manifestations of hypoglycemia including dizziness, lack of energy,&nbsp; drowsiness,&nbsp; headache and sweating have &nbsp;been&nbsp; observed and&nbsp; weakness,&nbsp; nervousness, shakiness and paresthesia have also been reported. All sulfonylurea drugs can induce severe hypoglycemia. Particularly susceptible are elderly subjects, patients with impaired hepatic or renal function, those who are debilitated or malnourished and patients with primary or secondary adrenal insufficiency. Some cases may be severe and prolonged. Hospitalisation may be necessary and glucose administration may need to be continued for several days. Hypoglycemia may be difficult to recognize in elderly patients and in patients receiving beta-blockers.</p><p>Possible other symptoms of hypoglycaemia are: intense hunger, nausea, vomiting, lassitude, sleep disorders, agitation, aggression, poor concentration, reduced awareness and slowed reactions, depression, confusion, visual and speech disorders, aphasia, tremor, paresis, sensory disorders, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness and loss of consciousness, possibly resulting in coma and lethal outcome. In addition, signs of adrenergic counter-regulation may be observed: clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmia.</p><p>This treatment should only be prescribed if the patient is likely to have a regular food intake (including breakfast). It is important to have a regular carbohydrate intake due to the increased risk of hypoglycemia if a meal is taken late, if an inadequate amount of food is consumed or if the food is low in carbohydrate. Hypoglycemia is more likely to occur during periods of low- calorie diet, following prolonged or strenuous exercise, following alcohol intake or during the administration of a combination of hypoglycemic agents.</p><p>Usually, hypoglycemic symptoms disappear after intake of carbohydrates (sugar). However, artificial sweeteners have no effect. Experience with other sulphonylureas shows that hypoglycemia can recur even when measures prove effective initially.</p><p>If a hypoglycemic episode is severe or prolonged, and even if it is temporarily controlled by intake of sugar, immediate medical treatment or even hospitalisation are required.</p><p>Other factors which increase the risk of hypoglycemia are: overdose of CLAZ MR, certain endocrine disorders (thyroid disorders, hypopituitarism and adrenal insufficiency) as well as withdrawal of prolonged and/or high dose corticosteroid therapy, severe &nbsp;vascular disease (severe coronary heart disease, severe carotid impairment, diffuse vascular disease) and concomitant administration of certain medicines (see DRUG INTERACTIONS).</p><p>&nbsp;</p><p><u>Poor</u><u> </u><u>Blood</u><u> </u><u>Glucose Control</u></p><p>The efficacy of gliclazide, in reducing glucose to the desired level decreases over a long period of time in many patients: this may be due to progression in the severity of the diabetes, or to a reduced response to treatment. This phenomenon is known as secondary failure and should be distinguished from primary failure, when the drug is ineffective when prescribed as first-line treatment. Adequate dose adjustment and compliance with dietary measures should be</p><p>considered before classifying the patient as secondary failure. If a loss of adequate blood glucose-lowering response to CLAZ MR is detected, the drug should be discontinued.</p><p>In patients stabilized on gliclazide therapy, loss of blood sugar control may occur in cases of acute intercurrent disease such as a fever and serious infection, in stressful situations such as trauma or surgery, or if used concomitantly with herbs such as St. John&#39;s Wort <em>(Hypericum perforatum) </em>preparations or of any treatment that may interact with gliclazide metabolism (see DRUG INTERACTIONS &amp; Drug-Herb Interactions). Under these conditions, discontinuation of gliclazide extended release tablets and administration of insulin should be considered.</p><p>&nbsp;</p><p><u>Dysglycaemia</u></p><p>Fluoroquinolones should be used with caution in patients receiving Gliclazide modified release tablets. Hypoglycaemia and hyperglycaemia have been reported in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Careful monitoring of blood glucose is recommended in all patients taking Gliclazide modified release tablets and a fluoroquinoloneconcomitantly.</p><p>&nbsp;</p><p><u>Hematologic</u></p><p>Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD)-deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since CLAZ MR belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non- sulfonylurea alternative should be considered.</p><p>&nbsp;</p><p><u>Hepatic/Biliary/Pancreatic</u></p><p>The metabolism and excretion of sulfonylureas including CLAZ MR may be slowed in patients with impaired hepatic function. Isolated cases of impairment of liver function with cholestasis and jaundice, and hepatitis which can regress after withdrawal of the drug or may lead to life- threatening liver failure have been observed. Discontinue treatment if cholestatic jaundice appears. Therefore, CLAZ MR is contraindicated in patients with severe hepatic impairment (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS - Monitoring and Laboratory Tests).</p><p>&nbsp;</p><p><u>Peri-Operative</u><u> </u><u>Considerations</u></p><p>In patients stabilized on gliclazide therapy, loss of blood sugar control may occur in cases of acute intercurrent disease or in stressful situations such as trauma or surgery. Under these conditions, discontinuation of CLAZ MR (gliclazide) and administration of insulin should be considered (see WARNINGS AND PRECAUTIONS - Endocrine and Metabolism, Poor blood glucose control).</p><p>&nbsp;</p><p><u>Renal</u></p><p>The metabolism and excretion of sulfonylureas including CLAZ MR may be slowed in patients with impaired renal function. If hypoglycemia should occur in such patients, it may be prolonged and appropriate management should be instituted. Therefore, CLAZ MR is contraindicated in patients with severe renal impairment (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS &mdash; Monitoring and Laboratory Tests).</p><p>&nbsp;</p><p><u>Sensitivity/Resistance</u></p><p>Due to the presence of lactose in CLAZ MR 60 mg, patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption or the Lapp lactose deficiency should not take CLAZ MR 60 mg.</p><p>CLAZ MR 30 mg does not contain lactose.</p><p>&nbsp;</p><p><u>Skin</u><u> </u></p><p>Serious skin and hypersensitivity reactions including rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported.</p><p>&nbsp;</p><p><strong>Special</strong><strong> </strong><strong>Populations</strong></p><p><u>Pediatrics</u><u> </u><u>(&lt;</u><u> </u><u>18 years of age):</u></p><p>Safety and effectiveness of Gliclazide modified release tablets in children have not been established. Gliclazide modified release tablets is therefore not recommended for use in children and adolescents.</p><p>&nbsp;</p><p><u>Geriatrics</u><u> </u><u>(&ge; 65 years of age):</u></p><p>Efficacy and tolerance of Gliclazide modified release tablets prescribed using the same therapeutic regimen in subjects over 65 years, has been confirmed in clinical trials, however greater sensitivity of some older individuals cannot be ruled out.</p><p>Severe hypoglycemia can be induced by all sulfonylurea drugs. Elderly subjects are particularly susceptible.</p><p>&nbsp;</p><p><strong>Monitoring</strong><strong> </strong><strong>and Laboratory Tests</strong></p><p>Measurement of glycated haemoglobin levels (or fasting venous plasma glucose) is recommended in assessing blood glucose control. Blood glucose self-monitoring is also recommended.</p><p>Blood glucose control in a patient receiving Gliclazide modified release tablets treatment may be affected by fever, infection, surgical intervention or when used concomitantly with St. John&#39;s Wort <em>(Hypericum perforatum) </em>preparations. Close monitoring is required in these patients. In some cases, it may be necessary to administer insulin.</p><p>Hepatic function should be assessed before initiating therapy and the liver function should be assessed periodically in patients with mild to moderately impaired hepatic function.</p><p>In patients with mild to moderately impaired renal function, renal function should be assessed periodically. Blood glucose and glycated hemoglobin levels should be regularly monitored in all patients.</p><p>Elderly patients (malnourished, with impaired hepatic, renal, or adrenal function) will require periodic monitoring and special care.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Serious</strong><strong> </strong><strong>Drug</strong><strong> </strong><strong>Interactions</strong></p><p>The concomitant use of miconazole and gliclazide is contraindicated (see CONTRAINDICATIONS).</p><p>&nbsp;</p><p><strong>O</strong><strong>v</strong><strong>e</strong><strong>r</strong><strong>v</strong><strong>i</strong><strong>ew</strong></p><p>As a result of drug interaction, hypoglycemia may be potentiated when a sulfonylurea is used concurrently with agents such as: long-acting sulfonamides, tuberculostatics, NSAIDs, fibrates, monoamine oxidase inhibitors, salicylates, probenecid, beta-blockers, azole antifungal agents (oral and parenteral preparations), H2 receptor antagonists, angiotensin converting enzyme inhibitors and clarithromycin. In addition, while not approved for use with other antidiabetic agents, hypoglycaemia is potentiated when gliclazide is used in combination with other antidiabetic agents.</p><p>Certain drugs tend to induce hyperglycemia and may lead to loss of blood sugar control. These include diuretics (thiazides, furosemide), corticosteroids, oral contraceptives (estrogen plus progestogen), chlorpromazine, ritodrine, salbutamol, terbutaline and nicotinic acid in pharmacologic doses.</p><p>Barbiturates should be used with caution in patients receiving an oral hypoglycemic agent since they may reduce the hypoglycemic effect.</p><p>Sulfonylureas may potentiate the action of anticoagulants. Adjustment of the anticoagulant dose may be necessary.</p><p>&nbsp;</p><p><strong>Drug-Drug</strong><strong> </strong><strong>Interactions</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table</strong><strong> </strong><strong>2 &ndash; Established or Potential Drug-Drug Interactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:561px"><tbody><tr><td style="width:116px"><p><strong>Gliclazide</strong></p></td><td style="width:63px"><p><strong>Reference</strong></p></td><td style="width:130px"><p><strong>Effect</strong></p></td><td style="width:256px"><p><strong>Clinical</strong><strong> Comment</strong></p></td></tr><tr><td style="width:116px"><p><strong>Miconazole</strong><strong> </strong>(systemic route, oromucosal gel)</p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><u><strong>Contra-indicated combination.</strong></u></p><p>Increases the hypoglycaemic effect with possible onset of hypoglycaemic symptoms, or even coma.</p></td></tr><tr><td style="width:116px"><p><strong>Phenylbutazone</strong>&nbsp;(systemic route)</p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combination</u><u> </u><u>is</u><u> </u><u>not recommended.</u></strong>&nbsp;</p><p>Increases the hypoglycaemic effect of sulphonylureas (displaces their binding to plasma proteins and/or reduces their elimination). It is preferable to use a different anti inflammatory agent, or else to warn the patient and&nbsp;<strong><u>emphasise the importance of self-monitoring</u></strong></p><p>Where necessary, adjust the dose during and after treatment with the anti-inflammatory agent.</p></td></tr><tr><td style="width:116px"><p><strong>Other antidiabetic agents (insulins, acarbose, biguanides)</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u></strong></p><p>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>Beta-blockers</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations requiring precautions for use.</u> </strong>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>Fluconazole</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requiri</u><u>ng</u><u> </u><u>precautions</u><u> </u><u>for use.</u> </strong></p><p>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>Angiotensin</strong><strong> </strong><strong>converting</strong><strong> </strong><strong>enzyme</strong><strong> </strong><strong>inhibitors</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u> </strong></p><p>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>H2-receptor antagonists</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u> </strong>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>MAOIs</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u> </strong>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>Sulfonamides</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u> </strong></p><p>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>Nonsteroidal</strong><strong> </strong><strong>anti-</strong><strong> </strong><strong>inflammatory&nbsp;</strong><strong>agents</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u> </strong></p><p>Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur.</p></td></tr><tr><td style="width:116px"><p><strong>Clarithromycin</strong></p></td><td style="width:63px"><p>T</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemi</p></td><td style="width:256px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Combinations</u><u> </u><u>requir</u><u>ing</u><u> </u><u>precautions</u><u> </u><u>for use.</u></strong></p><p>May potentiate the hypoglycemic action of sulfonylurea agents.</p></td></tr></tbody></table></td></tr><tr><td style="width:116px"><p><strong>Chlorpromazine</strong>&nbsp;(neuroleptic agent)</p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Causes an increase in blood glucose levels</p></td><td style="width:256px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Combination</u><u> </u><u>requiring</u><u> </u><u>precautions</u><u> </u><u>during</u><u> </u><u>use.</u></strong></p><p>High doses (&gt;100 mg&nbsp;per day of chlorpromazine) increase blood glucose levels (reduced insulin release).</p><p>Warn the patient and emphasise&nbsp;the importance of blood glucose monitoring. It may be&nbsp;necessary to adjust the dose of the antidiabetic active substance during and after treatment with the neuroleptic agent.</p></td></tr></tbody></table></td></tr><tr><td style="width:116px"><p><strong>Glucocorticoids</strong><strong> </strong>(systemic and local route: intra-articular, cutaneous and rectal preparations) and tetracosactide</p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Causes an increase in blood glucose levels</p></td></tr></tbody></table></td><td style="width:256px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>Combination</u><u> </u><u>requiring</u><u> </u><u>precautions</u><u> </u><u>during</u><u> </u><u>use&nbsp;</u></strong></p><p>Increase in blood glucose levels with possible ketosis (reduced tolerance to carbohydrates due to glucocorticoids).</p><p>Warn the patient and emphasise the importance of blood glucose monitoring, particularly at the start of treatment. It may be necessary to adjust the dose of the antidiabetic active substance during and after treatment with glucocorticoids.</p></td></tr></tbody></table></td></tr><tr><td style="width:116px"><p><strong>Ritodrine,</strong><strong> </strong><strong>salbutamol,</strong><strong> </strong><strong>terbutaline</strong><strong> </strong>(I.V.)</p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Causes an increase in blood glucose levels</p></td><td style="width:256px"><p><strong><u>Combination</u><u> </u><u>requiring</u><u> </u><u>precautions</u><u> </u><u>during</u><u> </u><u>use.</u> </strong></p><p>Increased blood glucose levels due to beta-2 agonist effects. Emphasise the importance of monitoring blood glucose levels. If necessary, switch to insulin.</p></td></tr><tr><td style="width:116px"><p><strong>Anticoagulant</strong><strong> </strong><strong>therap&nbsp;</strong>(Warfarin and other)</p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Potentiation of anticoagulation</p></td><td style="width:256px"><p><strong><u>Combination</u><u> </u><u>which</u><u> </u><u>must</u><u> </u><u>be</u><u> </u><u>taken</u><u> </u><u>into</u> <u>account.</u> </strong></p><p>Sulfonylureas may lead to potentiation of anticoagulation during concurrent treatment.</p><p>Adjustment of the anticoagulant may be necessary.</p></td></tr><tr><td style="width:116px"><p><strong>Drugs containing alcohol</strong></p></td><td style="width:63px"><p>C</p></td><td style="width:130px"><p>Increases the risk of hypoglycaemia</p></td><td style="width:256px"><p>Intolerance to alcohol (disulfiram-like reaction: flushing, sensation of warmth, giddiness, nausea and occasionally tachycardia) may occur in patients treated with sulfonylurea.</p></td></tr><tr><td style="width:116px"><p><strong>Fluoroquinolones</strong></p></td><td style="width:63px"><p>T</p></td><td style="width:130px"><p>Increases the risk of dysglycaemia</p></td><td style="width:256px"><p><strong><u>Combinations</u><u> requiring precautions for use.</u></strong></p><p>Warn the patient and emphasise the importance of monitoring blood glucose.</p></td></tr></tbody></table><p>Legend: C = Case Study; CT = Clinical Trial; T = Theoretical</p><p><strong>Drug-Food</strong><strong> </strong><strong>Interactions</strong></p><p>There are no established drug-food interactions.</p><p>&nbsp;</p><p><strong>Drug-Herb</strong><strong> </strong><strong>Interactions</strong></p><p>St. John&rsquo;s Wort</p><p>Pharmacodynamic interactions between gliclazide and the herbal remedy St. John&rsquo;s Wort may occur and may lead to hyperglycemia or loss of blood glucose control.</p><p>&nbsp;</p><p><strong>Drug-Laboratory</strong><strong> </strong><strong>Interactions</strong></p><p>Interactions with laboratory tests have not been established.</p><p>&nbsp;</p><p><strong>Drug-Lifestyle</strong><strong> </strong><strong>Interactions</strong></p><p>This treatment should only be prescribed if the patient is likely to have a regular food intake (including breakfast). It is important to have a regular carbohydrate intake due to the increased risk of hypoglycemia if a meal is taken late, if an inadequate amount of food is consumed or if the food is low in carbohydrate. Hypoglycemia is more likely to occur during periods of low- calorie diet and following prolonged or strenuous exercise.</p><p>Intolerance to alcohol (disulfiram-like reaction: flushing, sensation of warmth, giddiness, nausea and occasionally tachycardia) may occur in patients treated with sulfonylurea. Alcohol increases the hypoglycaemic reaction (by inhibiting compensatory reactions) that can lead to the onset of hypoglycaemic coma. Avoid alcohol or medicines containing alcohol.</p><p>Treatment with CLAZ MR can have effects on ability to drive and use machines. Patients should be made aware of the symptoms of hypoglycaemia and should be careful if driving or operating machinery, especially at the beginning of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnant</strong><strong> </strong><strong>Women:</strong></p><p>Gliclazide is contraindicated in pregnancy. It is recommended that insulin be used during pregnancy in diabetic women (see CONTRAINDICATIONS).</p><p>Uncontrolled diabetes (gestational or not) is associated with a higher incidence of congenital abnormalities and perinatal mortality. Blood glucose control should be optimal around the time of conception to reduce the risk of congenital malformations.</p><p>&nbsp;</p><p><strong>Nursing</strong><strong> </strong><strong>Women:</strong></p><p>CLAZ MR (gliclazide) is contraindicated in breast-feeding mothers. Some sulfonylurea drugs are excreted in human milk although it is not known whether gliclazide is one of them. Because the potential for hypoglycemia in nursing infants may exist, the product is contraindicated in breast-feeding mothers (see CONTRAINDICATIONS).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be made aware of the signs and symptoms of hypoglycaemia and should be careful if driving or operating machinery, especially at the beginning of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adverse</strong><strong> </strong><strong>Drug</strong><strong> </strong><strong>Reaction</strong><strong> </strong><strong>Overview</strong></p><p>Gliclazide modified release tablets 30 mg has been evaluated for safety in controlled clinical trials in 955 patients, of which 728 were treated in long-term studies for up to 10 months, in comparison with gliclazide 80 mg tablets.</p><p>The most frequent adverse drug reactions are hypoglycaemia and gastrointestinal disturbances (including abdominal pain, nausea, vomiting, dyspepsia, diarrhea, constipation).</p><p>Serious adverse drug reactions that resulted in hospitalization during clinical trials were malaise, acute renal failure, and thrombophlebitis.</p><p>&nbsp;</p><p><strong>Clinical Trial Adverse Drug Reactions</strong></p><p>Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.</p><p>&nbsp;</p><p><strong>Hypoglycemia</strong></p><p>Severe hypoglycemia which mimics acute CNS disorders may occur. Hepatic and/or renal impairment, malnutrition, debility, advanced age, alcoholism, adrenal or pituitary insufficiency may be predisposing factors.</p><p>In long-term studies, the percentage of patients experiencing hypoglycemic episodes was similar between patients treated with gliclazide modified release tablets 30 mg (11.6%) and those treated with gliclazide 80 mg tablets (11.1%). However, the number of hypoglycemic episodes for 100 patient-months was lower in the gliclazide modified release tablets 30 mg group (3.5) than in the gliclazide 80 mg tablets group (4.8).</p><p>Analysis in elderly patients (over 65 years old) showed that this population experienced, overall, less hypoglycemia than the whole population with a prevalence of hypoglycemic episodes lower in the gliclazide modified release tablets 30 mg group (2.6 hypoglycemic episodes for 100 patient-months) than in the gliclazide 80 mg tablets group (4.1).</p><p>&nbsp;</p><p><strong>Other</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>events</strong></p><p>Adverse events reported during controlled clinical trials with gliclazide modified release tablets 30 mg were those expected in the population of interest, a population whose underlying disease is recognized atheromatous risk factor.</p><p>Adverse events that have been reported in at least 1.0% of diabetic patients in long-term controlled studies, whatever their relationship to treatment, are listed by body system in Table 1. The most frequent adverse events were unspecific of the disease as respiratory infections or back pain.</p><p>&nbsp;</p><p><strong>Table</strong><strong> </strong><strong>1 &ndash; Adverse events reported in &ge;1% of type 2 diabetic patients in long-term controlled studies with Gliclazide Modified Release Tablets 30 mg <em>vs. </em>Gliclazide 80 mg</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="1" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="1" colspan="1" style="vertical-align:top"><p>Gliclazide</p><p>30 mg Modified Release Tablets</p><p>(n= 728)</p><p>%</p></td><td style="vertical-align:top"><p>Gliclazide</p><p>80 mg tablets</p><p>(n=734)</p><p>%&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Resistance</strong><strong> </strong><strong>mechanism</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infection viral</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>5.6</p></td></tr><tr><td style="vertical-align:top"><p>Otitis media</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory</strong></p><p>Rhinitis</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>4.4</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>4.6</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>4.6</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>3.5</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory infection</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Coughing</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculo-skeletal</strong></p><p>Back pain</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>5.2</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>4.1</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>3.5</p></td></tr><tr><td style="vertical-align:top"><p>Arthrosis</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Tendinitis</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p><strong>Secondary</strong><strong> </strong><strong>term</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Inflicted injury</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>4.5</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body as a whole</strong></p><p>Headache</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.8</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>4.6</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiovascular</strong></p><p>Hypertension</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.2</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>Oedema legs</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>U</strong><strong>r</strong><strong>inary</strong></p><p>Urinary tract infections</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong></p><p>Diarrhea</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.5</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Central,</strong><strong> </strong><strong>periph.</strong><strong> nervous system</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Neuralgia</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong><strong> </strong><strong>and nutrition</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycemia</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>11.1</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.2</p></td></tr><tr><td style="vertical-align:top"><p>Lipid metabolism disorder</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Hyperlipaemia</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong><strong> </strong><strong>and appendages disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dermatitis</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Skin disorder</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Pruritis</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vision disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>2.0</p></td></tr></tbody></table><p>Analysis of adverse events in sub-populations led to similar pattern as in the whole population and showed that sex, age and renal insufficiency had no significant influence on the safety profile of 30 mg.</p><p>&nbsp;</p><p><strong>Less</strong><strong> </strong><strong>Common</strong><strong> </strong><strong>Clinical</strong><strong> </strong><strong>Trial</strong><strong> </strong><strong>Adverse</strong><strong> </strong><strong>Drug</strong><strong> </strong><strong>Reactions</strong><strong> </strong><strong>(&lt;1%)</strong></p><p>Adverse events other than those already specifically mentioned in this product monograph and that have been reported with gliclazide modified release tablets 30 mg during long-term studies in more than one patient and/or that have been previously reported with gliclazide 80 mg tablets or with other sulfonylurea drugs include the following (drug relationship has not been proved for all cases):</p><p>&nbsp;</p><p><strong><em>Body as a whole: </em></strong>allergy, carpal tunnel syndrome, chest pain, fever, infection, fungal infection, leg pain, malaise, pain, weight increase.</p><p><strong><em>Cardiovascular: </em></strong>arteritis, cardiac failure, cerebrovascular disorder, coronary artery disorder, epistaxis, hypotension, myocardial infarction, palpitation, tachycardia, thrombophlebitis, vein disorder.</p><p><strong><em>Central,</em></strong><strong><em> </em></strong><strong><em>peripheral</em></strong><strong><em> </em></strong><strong><em>nervous system:</em></strong><strong><em> </em></strong>anxiety, confusion, depression, insomnia, nervousness, neuropathy.</p><p><strong><em>Endocrine: </em></strong>hypothyroidism. A decrease in the uptake of radioactive iodine by the thyroid gland has been reported with other sulfonylurea drugs. This has not been shown with gliclazide 80 mg tablets during a study involving 15 patients.</p><p><strong><em>Gastrointestinal: </em></strong>abdominal pain, anal fissure, appetite increased, colitis, duodenal ulcer, epigastric fullness, faecal incontinence, flatulence, gastric irritation, gastroesophageal reflux, GI neoplasm benign, hemorrhoids, melena, dry mouth, oesophagitis, saliva increased, tooth ache, tooth disorder, vomiting. These reactions are generally dose-related and may disappear when the dose is reduced.</p><p><strong><em>Hearing</em></strong><strong><em> </em></strong><strong><em>and</em></strong><strong><em> </em></strong><strong><em>vestibular:</em></strong><strong><em> </em></strong>hearing decreased, tinnitus.</p><p><strong><em>Liver and biliary: </em></strong>increased liver enzymes, hepatitis, hepatomegaly.</p><p><strong><em>Metabolic and nutritional: </em></strong>gout, glycosuria, hypercholesterolemia, hypertriglyceridemia, thirst. Cases of hepatic porphyria and disulfiram-like reactions have been described with sulfonylurea drugs. Clinical experience to date has shown that gliclazide 80 mg tablets has a low incidence of disulfiram type reactions.</p><p><strong><em>Musculo-skeletal: </em></strong>arthropathy, bursitis, hernia congenital, skeletal pain, spine malformation.</p><p><strong><em>Reproductive: </em></strong>balanoposthitis, benign female breast neoplasm, impotence, mastitis, menstrual disorder, prostatic disorder, vaginitis.</p><p><strong><em>Respiratory:</em></strong><strong><em> </em></strong>asthma, dyspnea, tracheitis.</p><p><strong><em>Skin and appendages: </em></strong>fungal dermatitis, eczema, erythema, hyperkeratosis, maculopapular or morbiliform rash, nail disorder, onychomycosis, pruritus, dry skin, skin ulceration, urticaria. These reactions may persist during treatment, which must be then interrupted. Cases of porphyria tarda and of photosensitivity have also been described with sulfonylurea drugs.</p><p><strong><em>Urinary: </em></strong>albuminuria, cystitis, nocturia, polyuria, renal calculus, renal cyst.</p><p><strong><em>Vision: </em></strong>cataract, conjunctival haemorrhage, diplopia, glaucoma, abnormal lacrimation, retinal disorder, abnormal vision, vitreous disorder, xerophthalmia.</p><p>&nbsp;</p><p><strong>Abnormal</strong><strong> </strong><strong>Hematologic</strong><strong> </strong><strong>and Clinical Chemistry Findings</strong></p><p>The pattern of laboratory tests abnormalities previously observed with gliclazide 80 mg tablets was similar to that for other sulfonylureas. Occasional mild to moderate elevations of hepatic enzymes, LDH and creatinine and decrease in natremia have been observed. These abnormalities frequently encountered with treated or untreated diabetic patients are rarely associated with clinical symptoms and generally not considered to be drug related. As with all hypoglycemic sulfonylurea drugs, a few rare cases of leukopenia, agranulocytosis, thrombocytopenia and anemia have been reported with gliclazide 80 mg tablets. No laboratory test abnormalities other than those already reported with gliclazide 80 mg tablets have been observed during controlled clinical trials performed on gliclazide modified release tablets 30 mg.</p><p>&nbsp;</p><p><strong>Post-Market</strong><strong> </strong><strong>Adverse</strong><strong> </strong><strong>Drug Reactions</strong></p><p>In post-marketing experience with gliclazide modified release tablets, gastrointestinal disturbance, including abdominal pain, nausea, vomiting, dyspepsia, diarrhea and constipation have been reported. Skin and subcutaneous tissue disorders, rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported.</p><p>The most serious adverse drug reactions reported with gliclazide are hypoglycaemic coma, pancytopenia, thrombocytopenia, hepatitis, cholestatic jaundice, pyrexia, pancreatitis acute and skin reactions (pruritus and rash).</p><p>The following adverse events have also been observed with gliclazide: cases of erythrocytopenia, agranulocytosis, hemolytic anemia, allergic vasculitis, hyponatremia, and elevated liver enzyme levels (AST, ALT, alkaline phosphatase); isolated cases of impairment of liver function with cholestasis and jaundice which can regress after withdrawal of the drug or may lead to life- threatening liver failure. Discontinue treatment if cholestatic jaundice appears.</p><p>&nbsp;</p><p>-&nbsp; To report any side effects:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>Overdosage with sulfonylureas may result in hypoglycemia but it should be noted that the dosage which causes such hypoglycemia varies widely and may be within the accepted therapeutic range in sensitive individuals.</p><p>The manifestations of hypoglycemia include sweating, flushing or pallor, numbness, chilliness, hunger, trembling, headache, dizziness, increased pulse rate, palpitations, increased blood pressure and apprehensiveness in mild cases. In more severe cases, coma appears.</p><p>However, symptoms of hypoglycemia are not necessarily as typical as those described above and sulfonylureas may cause insidious development of symptoms mimicking cerebrovascular insufficiency.</p><p>&nbsp;</p><p><strong>Treatment</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Overdosage</strong></p><p>Discontinue medication and treat hypoglycemia by giving dextrose promptly and in sufficient quantity.</p><p>Some sulfonylurea-induced hypoglycemias may be refractory to treatment and susceptible to relapse especially in elderly or malnourished patients. Continuous dextrose infusions for hours or days have been necessary.</p><p>Strict monitoring should be continued until the doctor is sure that the patient is out of danger.</p><p>Severe hypoglycaemic reactions, with coma, convulsions or other neurological disorders are possible and must be treated as a medical emergency, requiring immediate hospitalization.</p><p>Dialysis is of no benefit to patients due to the strong binding of gliclazide to proteins.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC Code: A10BB09</p><p>&nbsp;</p><p><strong>Hypoglycemic</strong><strong> </strong><strong>activity</strong></p><p>The main mechanism of action of gliclazide consists of an increase in the insulin secretory potential of pancreatic beta-cells in a situation of hyperglycemia. This effect of gliclazide on insulin secretion is maintained during long-term treatment in type 2 diabetic patients. It was observed that the administration of gliclazide was followed by:</p><ul><li>a consistent and significant decrease in fasting blood glucose;</li><li>a more than 1% decrease in mean glycated hemoglobin;</li><li>an inhibition by 12 to 27% of the rise in blood glucose after a standard meal or an oral glucose load.</li></ul><p>&nbsp;</p><p>A slight and transitory increase in mean fasting plasma insulin levels was occasionally observed with gliclazide treatment.</p><p>Regarding the biphasic nature of insulin secretion, the first peak that is severely blunted in type 2 diabetes is improved during gliclazide treatment.</p><p>In addition to the effect of gliclazide on the secretion of insulin, extrapancreatic effects have also been evidenced. Gliclazide improves peripheral sensitivity to insulin and increases glucose utilization rate:</p><ul><li>with euglycemic hyperinsulinemic clamps in obese and non-obese type 2 diabetic patients, it has been shown that gliclazide, after 3 months of treatment, increases the disappearance rate and metabolic clearance of glucose at the highest insulin infusion rates (100 and 300 mU/kg/h);</li><li>in comparison to diet treatment, gliclazide also enhances insulin-stimulated glucose</li><li>metabolism after 8 weeks of treatment by potentiating insulin action on skeletal muscle glycogen synthetase.</li></ul><p>Studies on glucose turnover have also shown that basal hepatic glucose production, measured by tracer methodology, was markedly reduced (28-50%) after 3 months of treatment.</p><p>&nbsp;</p><p><strong>Hemovascular</strong><strong> </strong><strong>activity</strong></p><p>Gliclazide possesses anti-platelet properties which are independent of its antidiabetic action, and improves the fibrinolytic potential in diabetic patients:</p><ul><li>numerous studies have shown inhibitory effects of gliclazide on platelet aggregation and hyperadhesiveness.</li><li>A statistically significant 22% decrease in collagen-induced platelet aggregation has been observed after 3 and 6 months of treatment with gliclazide in 15 patients previously well controlled under glibenclamide. A concentration-dependent inhibition of PAF-induced platelet aggregation has also been reported with gliclazide <em>in vitro </em>in platelet-rich plasma from healthy subjects and type 2 diabetic patients. Finally, a consistent decrease in markers of platelet activation (e.g. beta thromboglobuline and thromboxane B2 levels) has been observed with gliclazide whether glycemic control improved or not; change to gliclazide of patients treated since several years by chlorpropamide is followed by normalisation of the t-PA activity, sustained over 24-48 months. This has been confirmed by 2 studies in type 1 and glibenclamide-treated type 2 diabetics: in both, the addition of gliclazide to insulin or the switch to this sulfonylurea were followed by significant increase in t-PA and in the activity of the intrinsic fibrinolytic system.</li></ul><p>&nbsp;</p><p><strong>Antioxidant</strong><strong> </strong><strong>activity</strong></p><p>Gliclazide is a strong free radical scavenging agent, an effect demonstrated both <em>in vitro </em>and in patient. In 17 type 2 diabetic patients switched to gliclazide and seen at regular intervals during a 36-week period, peroxidized lipids and oxidized damaged IgG decreased significantly. These effects of gliclazide on the oxidative stress have been confirmed in a double-blind study in diabetic patients. Highly significant and sustained decrease in peroxidized lipid levels and increase in erythrocyte superoxide dismutase activity were obtained with gliclazide, but not with glibenclamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong></p><p>Gliclazide is slowly and completely absorbed from the gastro-intestinal tract (mean absolute bioavailability of 97%).</p><p>After administration, plasma concentrations rise gradually and the maximum concentration is usually reached after about 6 hours, with a plateau maintained for another 4 to 6 hours. Intra- individual variability is low. Food intake does not affect the rate and extent of absorption. The relationship between the dose administered and the area under the concentration curve as a function of time is linear. Linear kinetics were observed with gliclazide modified release tablets 30 mg in the dose range up to 120 mg.</p><p>&nbsp;</p><p><strong>Distribution:</strong></p><p>The volume of distribution is relatively small, which can partially be explained by high protein binding (about 95%).</p><p>A single daily dose of Gliclazide modified release tablets 30 mg maintains effective gliclazide plasma concentrations over 24 hours.</p><p>&nbsp;</p><p><strong>Metabolism:</strong></p><p>Although more than 90% of unchanged gliclazide is found in plasma following oral administration, this is extensively metabolized with little of the unchanged compound (&lt;1%) found in urine. Six principal metabolites have been identified in urine, essentially oxidized and hydroxylated derivatives, and two glucuronoconjugates. No active metabolites have been detected in plasma.</p><p>&nbsp;</p><p><strong>Excretion:</strong></p><p>Gliclazide metabolites and conjugates are primarily (60 to 70%) eliminated via the urine, with about 10 to 20% elimination via feces.</p><p>The mean elimination half life is 16 h (range 12 to 20 h).</p><p>&nbsp;</p><p><strong>Special</strong><strong> </strong><strong>Populations</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Conditions</strong></p><p><strong>Pediatrics: </strong>Safety and effectiveness of gliclazide in children have not been established. Gliclazide is therefore not recommended for use in children and adolescents.</p><p><strong>Geriatrics: </strong>No clinically significant modifications in the pharmacokinetic parameters have been observed in elderly patients.</p><p><strong>Gender: </strong>No significant relationship was found between any of the pharmacokinetic parameters and the covariates gender, body weight and creatinine clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each tablet of CLAZ MR 30 mg contains: Drug substance: 30 mg gliclazide</p><p>Excipients: colloidal silicon dioxide, hydroxypropyl methylcellulose and stearic acid</p><p>Each tablet of CLAZ MR 60 mg contains: Drug substance: 60 mg gliclazide</p><p>Excipients: colloidal silicon dioxide, hypromellose, lactose, stearic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>&nbsp;</em>Strength</strong></p></td><td style="vertical-align:top"><p><strong>Unit</strong><strong> </strong><strong>C</strong><strong>o</strong><strong>un</strong><strong>t or Fill Size</strong></p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em>Container<strong> </strong>Size(s)</strong></p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em>Description</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>30 mg</p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>30&rsquo;s</p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p><p>Blisters</p></td><td style="vertical-align:top"><p><strong><u>Film</u></strong><strong><u> </u></strong><strong><u>PVC/PVdC </u></strong><strong><u>Clear</u></strong><strong><u> 10</u></strong><strong><u> </u></strong><strong><u>MIL</u></strong><strong><u> </u></strong><strong><u>205/60</u></strong><strong><u> </u></strong><strong><u>205MM:</u></strong></p><p>Clear transparent plastic film, smooth on both sides. Approximately 205 mm wide.</p><p><strong><u>Foil</u></strong><strong><u> </u></strong><strong><u>Silver </u></strong><strong><u>Plain 205MM</u></strong><strong><u> 25&micro;M:</u></strong></p><p>Dull silver on one side, shiny silver on other. Rolled material approximately 205 mm wide.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong>60 mg</p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong>30&rsquo;s</p></td><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong>Blisters</p></td><td style="vertical-align:top"><p><strong><u>Film</u></strong><strong><u> </u></strong><strong><u>PVC/PVdC </u></strong><strong><u>Clear</u></strong><strong><u> 10</u></strong><strong><u> </u></strong><strong><u>MIL</u></strong><strong><u> </u></strong><strong><u>205/60</u></strong><strong><u> </u></strong><strong><u>205MM:</u></strong></p><p>Clear transparent plastic film, smooth on both sides. Approximately 205 mm wide.</p><p><strong><u>Film</u></strong><strong><u> </u></strong><strong><u>PVC/PVdC </u></strong><strong><u>Clear</u></strong><strong><u> 10</u></strong><strong><u> </u></strong><strong><u>MIL</u></strong><strong><u> </u></strong><strong><u>205/60</u></strong><strong><u> </u></strong><strong><u>205MM</u></strong></p><p>Clear transparent plastic film, smooth on both sides. Approximately 205 mm wide.</p><p><strong><u>Cold</u></strong><strong><u> Formable Foil 205MM:</u></strong></p><p>Dull silver on one side, shiny silver on other. Rolled material approximately 205 mm wide..</p><p><strong><u>Foil</u></strong><strong><u> </u></strong><strong><u>Silver </u></strong><strong><u>Plain 205MM</u></strong><strong><u> 25&micro;M:</u></strong></p><p>Dull silver on one side, shiny silver on other. Rolled material approximately 205 mm wide</p><p><strong><u>Foil </u></strong><strong><u>White</u></strong><strong><u> </u></strong><strong><u>Coated 205MM</u></strong><strong><u> 25&micro;M:</u></strong></p><p>Light grey on one side, dull silver on other. Rolled material approximately 205 mm wide.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated 
150 Signet Drive 
Toronto, Ontario 
Canada, M9L 1T9
Tel: 1-800-268-4623, Fax: 1-800-609-9444
www.apotex.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>